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1. Introduction
The American Cancer Society estimates that 76,250 Americans will be diagnosed with malig‐
nant melanoma and 9,180 will die from the disease in 2012 [1]. The incidence is increasing both in
the United States and worldwide [2]. Brain metastasis is a common problem in this population
with 45-60% of those with metastatic melanoma developing brain metastases during the course
of their illness [3]. Post-mortem studies demonstrate that brain lesions are present in 70-90% of
patients who die of melanoma [3]. Development of brain metastases may have adverse impact
both on a patient’s prognosis and, if symptomatic, severe effects on quality-of-life (QOL) [4]. If left
untreated, symptomatic brain lesions may be fatal within several weeks [3].
The literature pertaining to the treatment of brain metastasis from melanoma is scant when
compared to brain metastases from more common solid tumors. In particular, brain metastases
from non-small cell lung cancer (NSCLC) and breast cancer have been the subject of a larger
number of investigative efforts. This chapter will extrapolate relevant results from other
common solid tumors to the treatment of melanoma. In addition, systemic treatment ap‐
proaches that may be useful in managing intracranial disease will be presented. Leptomenin‐
geal involvement of the central nervous system, a less common form of central nervous system
(CNS) invasion by melanoma, will not be discussed.
2. Treatment modalities
2.1. Surgery
Three randomized trials have investigated treatment of a single brain metastasis with whole
brain radiation therapy (WBRT) alone or combined with surgical resection (Table 1) [5-7]. In
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all three, overall survival (OS) was the primary endpoint. In one study, the addition of surgery
to WBRT achieved better control at the target lesion site than did WBRT alone [7]. Two of the
trials indicated a survival benefit conferred by surgical treatment when added to WBRT,
compared to WBRT alone. Differences in the proportion of patients with NSCLC, percentages
of patients with extracranial disease, treatment of patients with non-metastatic intracranial
disease, and cross-over from one treatment arm to the other may explain why the study of
Mintz and co-workers did not indicate a survival benefit [6]. Extent of extracranial disease
status was a consistent predictor of survival.
Study Centers
(#)
Patients
(#)
Disease
Types
# (%)
Median
Survival
Recurrence/
Progression in CNS
Comments
Treated
Site
Distant
Patchell et al.,
1990 [7]
1 48
25-S
23-R
37 NSCLC
(77%)
3 Mel.
(6%)
40 w-S
15 w-R
P<0.01
20%-S
52%-R
P<0.02
20%-S
13%-R
P=0.52
37% of enrolled patients
with metastatic disease at
enrollment. Extracranial
disease and older age
predicted decreased survival
in multivariate analysis.
Noordijk et
al., 1994 [5]
5 63
32-S
31-R
33 NSCLC
(52%)
6 Mel.
(10%)
10 m-S
6 m-R
P=0.04
NR NR Survival benefit in those with
stable extra-cranial disease
(12 m-S vs. 7 m-R, p=0.02)
and patients younger than
61 y (19 m-S vs. 9 m-R,
p=0.003). No survival benefit
for surgery in patients with
progressive extracranial
disease or age"/>60.
Mintz et al.,
1996 [6]
8
84
41-S
43-R
45 NSCLC
(53%)
5.6 m-S
6.3 m-R
P=0.24
NR NR 45% of enrolled patients
with metastatic disease at
enrollment. Only extracranial
disease status predicted
survival in multivariate
analysis.
KPS: Karnofsky performance status; Mel: Melanoma patients; NR: Not reported; NSCLC: Non-small cell lung cancer; OS:
Overall survival; QOL: Quality of life; R: Refers to treatment arm receiving WBRT alone; S: Refers to treatment arm
combining surgery and WBRT
Table 1. Randomized trials of surgical resection of a single brain metastasis combined with WBRT versus WBRT alone
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Since these studies primarily enrolled patients with primary NSCLC or breast cancer, their
applicability to melanoma is uncertain. No prospective trials of surgery for melanoma patients
with brain metastases have been published to date. However, a number of large retrospective
studies have been reported (Table 2) [8-13]. Surgical treatment is consistently reported as a
factor strongly associated with prolonged survival over those treated with WBRT alone.
Selection biases are inherent in retrospective studies. Indeed, two of the studies specifically
identified factors predicting patient selection for more or less aggressive treatment and follow-
up based on the presumed severity of CNS involvement [10, 12]. Given that these retrospective
reports in melanoma concur with the randomized trials of surgical therapy in non-melanoma
brain metastases, similar randomized trials of surgery for melanoma brain metastases are
probably unnecessary.
Traditionally, surgical management of brain metastases was restricted to individuals with a
single accessible lesion. Bindal and co-workers found that individuals with a variety of primary
solid tumors (n=56; melanoma=25/45%) undergoing resection of 2-3 brain metastases had
survival rates equivalent to those undergoing resection of a single lesion [14]. In patients with
complete resection of all known lesions, median survival was 14 months, equivalent to that
for patients treated surgically for a single CNS lesion. Patients who could not undergo
complete resection of CNS disease demonstrated inferior median overall survival of 6 months.
Thus, presence of multiple CNS metastases is not a contra-indication to surgical treatment,
although the advent of stereotactic radiosurgery (SRS) has made this approach less common.
2.2. Stereotactic Radiosurgery (SRS)
Stereotactic radiosurgery (SRS) has become a major modality in the local treatment of brain
metastases. When compared to conventional techniques, SRS allows for safe and effective dose
escalation. This is achieved through use of multiple modulated beamlets from a variety of
angles, allowing optimized conformality and avoidance of normal tissues. SRS is minimally
or non-invasive and allows targeting multiple CNS lesions including those that may be
surgically accessible. Treatment is often performed on an outpatient basis and over a short
time duration. Retreatment of the same or of new lesions is possible.
The Radiation Therapy Oncology Group (RTOG) conducted a large randomized study of SRS
combined with WBRT (n=164) versus WBRT alone (n=167) (Table 3) [15]. The study enrolled
patients with a variety of tumor types, although NSCLC patients comprised the largest
proportion. The addition of SRS to WBRT resulted in a survival benefit for patients with a
single brain lesion (6.5 months for combination therapy versus 4.9 months for WBRT alone,
p=0.0393), but not for patients with multiple lesions (5.8 months for combination therapy
versus 6.7 months for WBRT alone, p=0.9776) or all patients combined (6.5 months for the
combination versus 5.7 months for WBRT alone, p=0.1356). At 6 months, SRS-treated patients
required lower doses of corticosteroids and were more likely to discontinue steroid use
altogether (52% in SRS+WBRT decreased their dose compared to 33% in the WBRT only group,
p<0.0158). Patients receiving SRS also were more likely to improve their performance status
(13% improved vs. 4% improved in WBRT group, p=0.0331). Local control of targeted tumors
was better with SRS. Disease control at distant sites within the brain was equivalent.
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Study Dates, Patient Source
Population, Institution
Melanoma
Patients
Studied and
Treatment
Median Survival CNS
Recurrence
Rates Based
on Therapy
Received
QOL
Raizer et al.,
2008 [13]
1991-2001
All metastatic melanoma
patients (n=1114)
at a single center
355 total
12 S/R +SRS
20 S + SRS
58 S/R
20 R + SRS
36 S
26 SRS
100 R
83 Supp.
Surgery (9 m) vs. no
surgery (4 m),
p<0.0001
R 4.0 m
Supp. 2.0 m
NR NR
Fife et al.,
2004 [12]
1985-2000
All patients with brain
metastasis from
melanoma (n=1137)
at a single center
686 total
158 S/R
47 S
236 R
210 Supp.
All pts. 4.1 m
S/R 8.9 m
S 8.7 m
R 3.4 m
Supp. 2.1 m
S= S/R, p=0.21
S or S/R >R > Supp.,
p<0.001
NR NR
Buchsbaum et
al., 2002 [10]
1984-1998
All brain metastasis
patients (n=1154) at a
single center
74 total
14 S/R
19 R + SRS
3 S/R + SRS
10 S or SRS
25 R
3 Supp.
All pts. 5.5m
(S or SRS) + R 8.8 m
S or SRS 4.8 m
R 2.3 m
Supp. 1.1 m
(S or SRS) + R vs.
other groups,
p<0.0001
S/R =R + SRS,
p=0.5128
49% Local + R
17% R
20% S or SRS
NR
Zacest et al.,
2002 [11]
1979-1999
All surgically treated
melanoma patients with
brain metastasis at a
single center
147 total
9 S
102 S/R
33 S/R/C
3 S/C
All pts. 8.5 m 50% overall
recurrence
rate
Neurological
symptoms
after
treatment:
Resolved
52%
Improved
26%
Unchanged
9%
N/A 13%
Wronski and
Arbit, 2000 [9]
1974-1994 91 total
49 S/R
All pts. 6.7 m 56% S/R vs.
46% S, p=NR
NR
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Study Dates, Patient Source
Population, Institution
Melanoma
Patients
Studied and
Treatment
Median Survival CNS
Recurrence
Rates Based
on Therapy
Received
QOL
All surgically treated
brain metastasis patients
(n=702) at a single
center
29 S
13 died within
62 d of surgery
S/R (9.5 m) vs. S (8.3
m), p=0.67
Sampson et
al., 1998 [8]
~1978-1998
All melanoma patients
(n=6953) treated at a
single center
524 total
87 S/R
52 S
180 R
205 C
Surgical therapy
(NR) vs. R (120 d),
p<0.0001
S/R (268 d) vs. S
(195 d), p=0.9998
R (120 d) vs. C (39
d), p<0.0006
NR No sig.
difference in
symptomati
c results
between
patients
treated with
surgery and
those
treated with
radiation
(p=0.138)
Skibber et al.,
1996 [53]
1979-1991
All surgically treated
melanoma patients with
a single brain metastasis
at two centers. No active
non-CNS metastases
present.
34 total
22 S/R
12 S
S/R (18 m) vs. S(6
m), p=0.002
Overall CNS
relapse rate:
30% S/R vs.
90% S, p=0.02
NR
Hagen et al.,
1990 [54]
1972-1987
All surgically treated
melanoma patients with
a single brain metastasis
at a single center
35 total
16 S
19 S/R
S (8.3 m) vs. S/R (6.4
m), p=NS
Median time
to CNS relapse:
S/R (26.6 m)
vs. S (5.7 m),
p<0.05
NR
C: Chemotherapy; Local Therapy: Treatment of CNS lesions with either surgery or stereotactic radiosurgery; KPS:
Karnofsky performance status; NR: Not reported; NS: not significant; OS: Overall survival; QOL: Quality of life; R: Whole
brain radiotherapy; S: Refers to treatment arm using surgery alone; Sig: Statistically significant; S/R: Surgery combined
with whole brain radiotherapy; SRS: Stereotactic radiosurgery; Supp: Supportive care;
Table 2. Retrospective case series of surgery as treatment for brain metastasis in melanoma
A smaller study used the same design, but its primary endpoint was local disease control in
patients with 2-4 brain lesions (Table 3) [16]. The study was halted at 60% of planned accrual
due to meeting its primary endpoint (27 patients; 5 with melanoma). SRS-treated patients had
significantly improved local disease control (p=0.0016). Median time-to-progression at SRS-
treated sites was 6 months in patients treated with WBRT alone, versus 36 months in those
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treated with SRS and WBRT (p=0.0005). Extracranial disease status was the major survival
determinant in a post hoc analysis.
Only two relatively small, single-arm prospective studies of SRS in melanoma have been
published. One of these studies enrolled 31 patients, including 14 (45%) with melanoma (Table
3) [17]. Patients received only SRS as CNS therapy. Overall intracranial failure rate was 50%
at 6 months. About one-third of patients failed within the SRS-treated tumor volume. The
second study enrolled 45 melanoma patients receiving SRS at one of two treatment centers
(Table 3) [18]. Up to 6 metastases were treated. Use of WBRT in conjunction with this therapy
was not reported. Median survival of all patients was 4.2 months. The local control rate with
SRS was 86%, although the follow-up period was not defined. Follow-up imaging was
available for only 71 out of 86 treated lesions.
Numerous retrospective studies have reported the results of SRS therapy in melanoma (Table
4) [19-41]. These are quite variable in design. While some studied melanoma patients exclu‐
sively, others enrolled patients with other tumor types. Several studies appear to include the
same set of patients treated at a given institution during overlapping time periods (noted in
Table 4). Treatment and follow-up plans were not pre-specified or standardized. Although all
patients received SRS, they often received a wide array of other therapies, including immediate
or delayed WBRT, concurrent or delayed surgery, and partial brain irradiation. Patients
received SRS both as primary brain metastasis therapy and as salvage therapy after failure of
prior treatment. Some patients received therapy for a single metastasis, while others were
treated for multiple brain metastases. Several studies specifically identify selection bias in the
treated population, with more aggressive therapy being reserved for patients with more severe
CNS disease [37, 38]. Collectively, the study heterogeneity limits the conclusions that can be
reached from these retrospective analyses.
Reported median survival of melanoma patients in these series ranged from 4.4 to 11.1 months.
These values approximate ranges reported in patients with brain metastases from other
primary tumor types, in which median survival is estimated to be 6.5 to 10.5 months [10, 42,
43]. Several factors predicted shorter survival in multiple studies: decreased performance
status or its surrogate indicators, multiple CNS lesions, greater intracranial tumor volume,
infratentorial lesion location, and active extracranial disease.
Some studies did not find that the initial number of lesions predicted survival [28, 29, 34, 37,
39]. This contradicts the results of the only randomized trial of SRS with survival as the primary
endpoint, in which a survival benefit was observed only in patients with a single CNS lesion
(OS was 6.5 months in patients with SRS+WRBT compared to 4.9 months in the WBRT group
alone; p=0.0393) [15]. This may be due to inadequate statistical power in the retrospective
studies, given the heterogeneity of the populations under study.
CNS disease control was reported in most of these retrospective studies as 1-year actuari‐
al control rates. At SRS-treated sites, reported in most of the studies, this was 47-87%. One-
year control at non-SRS treated sites was 24-57%. The overall CNS control at one year was
only 24-38%.
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Study Study Design Patient
Numbers &
Tumor Types
Treatment Median Survival CNS Recurrence
Andrews et al.,
2004 [15]
Randomized
Multi-institution,
cooperative
group study
1996-2001
Primary
endpoint:
median survival
331 total
64% Lung
10% Breast
5%
Melanoma
21% Other
1-3 CNS
metastases
164 SRS+R
167 R
Overall 6.5 m S+R
vs. 5.7 m R, p=0.14
Single met. 6.5 m
SRS+R vs. 4.9 m R,
p=0.39
Multiple met. 5.8
m SRS+R vs. 6.7 m
R, p=0.98
Time to intra-cranial
progression SRS+R=R,
p=0.13
Local control at 1 yr 82%
SRS+R vs. 71% R, p=0.01
Kondziolka et
al., 1999 [16]
Randomized
Single institution
Primary
endpoint: local
control at SRS-
treated site
27 total:
44% Lung
19%
Melanoma
15% Renal
15% Breast
7% Other
2-4 CNS
metastases
13 SRS+R
14 R
11 m SRS+R vs. 7.5
m R, p=0.22.
Median time to CNS
failure:
Local: 36 m SRS+R vs. 6 m
R, p=0.0005
Any: 34 m SRS+R vs. 5 m
R, p=0.002
Manon et al.,
2005 [17]
Single-arm
Multi-institution,
cooperative
group study
1998-2003
Primary
endpoint: 3m
and 6m
intracranial
progression rate
31 total
45%
Melanoma
45% Renal
10% Sarcoma
1-3 CNS
metastases
31 SRS 8.3 m Intra-cranial Failure Rates
3 m:
Any 25.8%
SRS-treated 19.3%
Outside SRS 16.2%
6 m:
Any 48.3%
SRS-treated 32.2%
Outside SRS field32.2%
Friehs et al.,
1998 [18]
Single-arm
Multi-institution
1998-2003
Primary
endpoint: Overall
survival
45 total
100% Mel.
1-6 CNS
metastases
45 SRS 4.2 m 86% of SRS-treated
tumors controlled at
follow-up.
13 (29%) with known
distant failure in CNS.
KPS: Karnofsky performance status; Mel: Melanoma; Met: Metastasis/metastases; MMSE: Mini-Mental Status Examina‐
tion; NR: Not reported; QOL: Quality of life; R: Whole brain radiotherapy; SRS+R: Stereotactic radiosurgery combined
with whole brain radiotherapy; SRS: Stereotactic radiosurgery
Table 3. Prospective trials of stereotactic radiosurgery as treatment for brain metastases in melanoma
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Study Study Design Patient
Numbers
& Tumor
Types
Treatment Median
Survival
CNS Control Rates
(1-yr actuarial
unless otherwise
stated)
Comments
(Prognostic factors
multivariate unless
otherwise noted)
Liew et al.,
2011 [31]
1987-2008
Single institution
All patients with mel.
receiving GK
344 total
100% mel.
163 SRS
118 SRS+R
63 SRS +
other
5.6 m after
SRS
8.3 m from
diagnosis of
brain met
SRS treated sites
63%
Distant 33%
R not sig. for survival or
recurrence.
Population may overlap
with that of Mori et al.,
1998 and Somoza et al.,
1993.
Hara et al.,
2009 [27]
1999-2005
Single institution
All pts. receiving
Cyberknife therapy for
mel. or renal cancer
62 total
44 mel.
18 renal
33 SRS
17 SRS sal.
5 SRS+R
7 SRS +
Surg.
8.3 m
5.6 m for
mel.
SRS-treated sites
87%
Local and distant
38%
Powell et al.,
2008 [34]
1998-2007
Single institution
All patients receiving
GK
76 total
50 mel.
23 renal
3 sarcoma
39 SRS
37 SRS+R
5.1 m
Histology
does not
predict
outcome
SRS-treated sites
78%
Distant 37%
Local and distant
26%
Local control higher for
renal than mel . (94% vs.
63%, p=0.001)
Redmond et
al., 2008
[36]
1998-2006
Single institution
All mel. pts. receiving
GK
59 total
100% mel.
32 SRS
27 SRS+R
4.4 m NR Timing between SRS and
R undefined.
Samlowski
et al., 2007
[37]
1999-2004
Single institution
All mel. patients
receiving LA-SRS
44 total
100% mel.
19 SRS
4 SRS
+partial R
14 SRS+R
16% SRS
with salvage
R
11.1 m from
brain
metastasis
diagnosis
48% 1-yr
survival
18% 2-yr
survival
SRS-treated sites
47%
Patients receiving SRS+R
had a higher mean
number of presented
metastases (3.8) than
those receiving salvage R
after SRS failure (1.6).
22 (50%) treated with
surgery at some point.
Multiple lesions treated
in 22 (50%).
Christopoul
ou et al.,
2006 [22]
1998-2004
Single institution
All mel. patients
receiving GK
29 total
100% mel.
All SRS
4 with prior
R
2 with prior
surg.
5.7 m NR
Gaudy-
Marqueste
et al., 2006
[23]
1997-2003
Single institution
All mel. patients
receiving GK
106 total
100% mel.
106 SRS 5.1 m
13% 1-yr
survival
SRS-treated sites
69%
No patients received
planned R
Chang et al.,
2005 [20]
1991-2002
Single Institution
189 total
103 mel.
77 renal
130 SRS
16 SRS + R
43 SRS sal.
7.5 m For mel.
SRS-treated sites
47%
Inadequate patients
treated with R to assess
effects.
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Study Study Design Patient
Numbers
& Tumor
Types
Treatment Median
Survival
CNS Control Rates
(1-yr actuarial
unless otherwise
stated)
Comments
(Prognostic factors
multivariate unless
otherwise noted)
All patients with mel.,
renal cancer or sarcoma
receiving SRS as therapy
9 sarcoma 24% 1-y
survival for
mel.
Distant 24%
Koc et al.,
2005 [29]
1999-2003
Single institution
All mel. patients
receiving GK as initial
therapy
26 total
100% mel.
12 SRS
14 SRS+R
6 m
25% 1-yr
survival
NR
Radbill et al.,
2004 [35]
1996-2001
Single institution
All mel. patients
receiving GK
64 total
100% mel.
32 SRS
13 SRS sal.
8 SRS+R
8 SRS+surg.
2 SRS + R +
surg.
1 NR
26 wk
Single CNS
met. (77 wk)
vs. multiple
(20 wk),
p=0.003
SRS-treated sites
56%
Distant 25%
Adjuvant R did not
decrease distant failure,
although small
population receiving it.
Selek et al.,
2004 [38]
1991-2001
Single institution
All mel. patients
receiving LA-SRS
103 total
100% mel.
61 SRS
12 SRS + R
30 SRS sal.
Overall 6.7
m
SRS 7.5 m
SRS+R 3.7 m
SRS sal. 5.4
m
25% 1-y
survival
SRS-treated sites
48%
SRS alone 60%
SRS+R 0%
SRS sal. 5%
Distant 24%
SRS alone 18%
SRS+R 0%
SRS sal. 51%
Patients with more
aggressive disease were
more likely to receive R
after SRS.
Herfarth et
al., 2003
[28]
1986-2000
Two institutions
All mel. patients treated
with LA-SRS
64 total
100% mel.
All SRS 10.6 m SRS-treated sites
81%
Lesions ≥2 cm
(64%) vs. <2 cm
(88%), p=0.05
Distant CNS control
NR
Brown et al.,
2002 [19]
1990-2000
Single institution
All patients with mel.,
renal cancer or sarcoma
receiving SRS.
41 total
23 mel.
16 renal
2 sarcoma
20 SRS
4 R with SRS
sal.
8 Surg. with
SRS sal.
9 SRS + surg.
14.2 m
No
difference
in survival
SRS+R vs.
SRS, p=0.54
6 m CNS control
SRS-treated sites:
SRS+R (100%) vs.
SRS (85%), p=0.02
Distant:
SRS+R (91%) vs.
SRS (35%), p=0.004
Gonzalez-
Martinez et
al., 2002
[25]
1996-2002
Single institution
All mel. patients
receiving GK
24 total
100% mel.
10 SRS
14 SRS+R
5.5 m NR
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Study Study Design Patient
Numbers
& Tumor
Types
Treatment Median
Survival
CNS Control Rates
(1-yr actuarial
unless otherwise
stated)
Comments
(Prognostic factors
multivariate unless
otherwise noted)
Mingione et
al., 2002
[32]
1989-1999
Single institution
All mel. patients
receiving GK
45 total
100% mel.
29 SRS
16 SRS+R
10.4 m
31% 1-yr
survival
NR Adjuvant R had no
impact on survival or
CNS recurrence rate.
Yu et al.,
2002 [41]
1994-1999
Single institution
All mel. patients
receiving GK
122 total
100% mel.
83 SRS
12 SRS + R
10 SRS/R
>1.5 m
before SRS
17 SRS/R
>1.5 m after
SRS
7 m
26% 1-yr
survival
SRS-treated sites
84%
Distant 57%
Population may overlap
with that of Lavine et al.,
1999 and Chen et al.,
1999.
Chen et al.,
1999 [21]
1994-1999
Single institution
All patients receiving
GK
199 total
88 mel.
40 NSCLC
5 SCLC
12 Renal
12 Breast
9 Colon
24 Other
199 SRS 8.5 m
7 m for mel.
89% of lesions with
follow-up
“controlled for the
lifetime of the
patient”
Use of R reported, but
not defined.
Population may overlap
with that of Yu et al.,
2002 and Lavine et al.,
1999.
Follow-up available for
only 69% of lesions.
Lavine et al.,
1999 [30]
1994-1997
Single institution
All mel. patients
receiving GK
45 total
100% mel.
43 SRS.
2 SRS + R
8 m 3 m CNS control
SRS-treated sites
97%
Distant 81%
Population may overlap
with that of Yu et al.,
1999 and Chen et al.,
1999.
Other therapies in
addition to SRS
depending on clinical
condition. Only 2 (4%)
received SRS+R
Grob et al.,
1998 [26]
1993-1996
Single institution
All mel. patients
receiving GK
35 total
100% mel.
35 SRS 7 m Actuarial control
rate of evaluable,
treated lesions:
3 m 98%
6 m 100%
9 m 95%
12 m 87%
Distant CNS control
not reported
Mori et al.,
1998 [33]
1988-1996
Single institution
All mel. patients
receiving GK
60 total
100% mel.
12 SRS
36 SRS+R
12 SRS sal.
7 m median
survival
21% 1-yr
survival
Control in 46 pts.
receiving SRS +/-R:
SRS-treated sites:
Overall 85%
Population may overlap
with that of Mathieu et
al., 2007 and Somoza et
al., 1993.
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Study Study Design Patient
Numbers
& Tumor
Types
Treatment Median
Survival
CNS Control Rates
(1-yr actuarial
unless otherwise
stated)
Comments
(Prognostic factors
multivariate unless
otherwise noted)
SRS+R 80%
SRS 100%
SRS sal. 86%
Distant:
Overall 70%
SRS+R 77%
SRS 56%
SRS sal. 57%
Seung et al.,
1998 [39]
1991-1995
Single institution
(UCSF)
All melanoma patients
receiving GK
55 total
100%
melanoma
28 SRS
11 SRS+ R
16 SRS sal.
35 wk SRS-treated sites
77%
Distant 36%
Entire CNS 24%
Gieger et al.,
1997 [24]
1992-1994
Single institution
All mel. patients
receiving LA-SRS
12 total
100% mel.
1 SRS
10 SRS+R
1 SRS sal.
8 m
36% 1-y
survival
At least 6 patients
with at least one
SRS-treated lesions
progressing.
At least 3 (25%)
developing new
distant CNS lesions
Imaging follow-up not
consistent.
Somoza et
al., 1993
[40]
1988-1992
Single institution
All mel. patients
receiving GK
23 total
100% mel.
19 SRS + R
4 SRS with R
3-12 m later
7 m
26% 1-y
survival
NR Population may overlap
with that of Mathieu et
al., 2007 and Mori et al.,
1998.
CNS: Central nervous system; GK: Gamma knife-based stereotactic radiosurgery; KPS: Karnofsky performance status; LA-
SRS: Linear accelerator-based stereotactic radiosurgery; Mel: Melanoma; Met: Metastasis/metastases; NR: Not reported;
QOL: Quality of life; Partial R: Partial brain irradiation; R: Whole brain radiotherapy; RPA: Recursive Partitioning Analysis;
Sig: Statistically significant; SIR: Score Index for Radiosurgery; SRS: Stereotactic radiosurgery; SRS+R: Stereotactic
radiosurgery combined with whole brain radiotherapy; SRS sal: Stereotactic radiosurgery salvage after failure of prior
therapy; SRS+Surg: Combination therapy of stereotactic radiosurgery and conventional surgical resection; Surg: Surgical
resection
Table 4. Retrospective studies of stereotactic radiosurgery for brain metastasis in melanoma
2.3. Comparative benefit of SRS versus surgery
The relative benefit of SRS versus surgery has not been tested in randomized clinical trials to
date. One small randomized trial indirectly addressed this question, although not specifically
for melanoma (Table 5) [44]. Sixty-four subjects with a single, surgically accessible brain lesion
were randomly assigned to surgical excision and adjuvant WBRT or to SRS alone. A direct
comparison of surgery and SRS is not possible due to the inclusion of adjuvant WBRT for all
surgical patients and its omission in SRS-treated patients. Nine (14%) of the subjects had
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melanoma. No difference in overall survival was observed (9.5 months for surgery versus 10.3
months for SRS, p=0.8). A statistically non-significant improvement in local tumor control
favored SRS (82% for surgery plus WBRT versus 97% for SRS, p=0.06). The one-year recurrence
rate at distant CNS sites was significantly higher in the group receiving SRS alone (3% for
surgery plus WBRT versus 26% for SRS alone, p<0.05). Thus, this study perhaps served to
highlight the risks of omitting adjuvant treatment, rather than the relative merits of SRS versus
surgery.
Two retrospective studies compared SRS to surgery [45, 46]. Melanoma patients were in the
minority in both studies. O’Neill and co-workers analyzed patients seen from 1991-1999 at the
Mayo Clinic who underwent either SRS or surgery for a solitary brain metastasis [45]. Eligible
patients were candidates for either procedure: all had solitary lesions measuring less than 35
mm (maximum size conventionally treated with SRS), none of the lesions were surgically
inaccessible, and none required immediate surgical decompression. Ninety-seven patients met
these criteria, of whom only seven were melanoma patients. Seventy-four were treated
surgically and twenty-three were treated with SRS. Although not achieving statistical signif‐
icance, more SRS-treated patients received WBRT (96% SRS vs. 82% surgery, p=0.172). The
treatment groups differed at baseline in performance status (worse in the SRS group, p=0.0016).
Overall survival was similar between the two groups and was predicted by age, performance
status, and systemic extracranial disease status rather than the type of brain metastasis
treatment. Similar proportions of patients had CNS recurrence (29% SRS versus 30% surgery),
but patients receiving surgery were more likely to have local recurrence at treated sites (58%
of recurrences in 19 patients vs. 0% out of 6 recurrences in SRS-treated patients, p=0.02).
Although this study suggests that local recurrences are more common after surgery, the
retrospective nature of the study and the small number of patients limits its applicability.
In contrast, another single institution, retrospective study from a similar time period
(1991-1994) suggested that SRS led to higher local recurrence rates than surgery [46]. Thirty-
one patients were treated with SRS and sixty-two with surgery for brain metastases. Twenty-
one patients (23%) had melanoma. Patients were matched with regard to histology,
extracranial disease status, performance status, time from initial diagnosis to CNS metastasis,
number of CNS metastases, age, and gender. Patients in the two groups were equally likely to
have received WBRT. Patients receiving surgical treatment survived significantly longer than
those treated with SRS (16.4 months surgery vs. 7.5 months SRS, p=0.0018). This improvement
in survival was attributable to decreased rates of death from neurological causes in the surgical
group (19% surgery vs. 50% SRS, p=0.037); deaths due to systemic disease were equivalent
(p=0.28). Surgery yielded lower local tumor recurrence rates than SRS (8.1% surgery vs. 38.7%
SRS). There was no statistically significant different in distant CNS recurrence rates between
the two groups.
This retrospective study is subject to the biases inherent in such an undertaking. The authors
matched patients for a variety of known relevant parameters, but the differences in local
control may reflect the use of older SRS technology, high quality neurosurgical treatment at
the referral center where the study was undertaken, or a combination of both. These discrep‐
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ancies might explain the differences in results when contrasted with the results of the two other
studies described [44, 45].
Collectively these studies do not indicate whether surgery or SRS is superior. There are no
easily detectable differences in local control rates. Logistic differences therefore are important
in selecting therapy. Unless a clinical situation arises in which surgery provides clear superi‐
ority (e.g. rapid control of symptomatic lesions; histological diagnosis), SRS will likely be the
predominant modality employed to treat macroscopic melanoma lesions in the CNS.
2.4. Adjuvant Whole Brain Radiotherapy (WBRT)
Adjuvant therapy of the CNS is that which is administered in conjunction with definitive local
therapy (surgery or SRS) of radiologically evident tumors to treat co-existing micrometastatic
disease. This is distinguished from prophylactic cranial irradiation (PCI). PCI is administered
in patients with systemic cancer after responses to systemic therapy, and has proven benefit
in several conditions, such as small cell lung cancer (SCLC) [47, 48]. In melanoma, PCI has not
been adequately assessed to recommend. Adjuvant CNS therapy has traditionally relied on
WBRT. Although new systemic agents with proven anti-melanoma activity and CNS pene‐
tration may come to be used for this purpose as well, such use is experimental at present.
Adjuvant WBRT is a controversial topic in metastatic brain tumor management, primarily due
to questions of efficacy and of neurocognitive toxicity.
Three factors must be considered in determining whether or not to use adjuvant WBRT: (a)
the effectiveness of WBRT in preventing emergence of new brain tumors; (b) the adverse effects
of WBRT; and (c) the competing adverse effect of foregoing WBRT, namely an increased rate
of CNS tumor progression. As new systemic therapies are proposed for this purpose, the same
considerations apply. The relevant adverse effects relate to deterioration of neurocognitive
function (NCF) and QOL, which could result from either WBRT itself or from progressive brain
tumors. It is in balancing these factors that a rational decision regarding the use, or non-use,
of adjuvant WBRT can be made.
2.4.1. Randomized trials of adjuvant WBRT in solid tumor patients
Despite the frequency of brain metastasis in melanoma patients, no prospective trials have
been conducted to assess adjuvant WBRT in this population. Data from the treatment of brain
metastases focusing on other tumor types must be reviewed to come to any conclusions (Table
5). Five randomized trials of adjuvant WBRT have been reported. Four of these are multi-
institutional efforts, reflecting the difficulty in conducting this type of study [49-52]. A fifth
study, discussed earlier, compared outcome in patients with a single brain metastasis treated
with surgery and WBRT or with SRS alone [44]. The majority of patients in all of the studies
were those with NSCLC primary tumors. Relatively few melanoma patients were enrolled.
Only one study used intracranial recurrence rate as the planned primary endpoint [52]. Ninety-
five patients were enrolled after surgical resection of an isolated brain metastasis. Sixty percent
had NSCLC. Forty-nine patients were randomized to receive adjuvant WBRT (50.4 Gy
administered as 28-1.8 Gy fractions). The remaining forty-six patients were observed. Only
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Study Evaluable
Patients
(#)
Disease types
#
Primary
Endpoint
Median
Survival
Recurrence/Progression
in CNS
Comments
S/SRS-site Distant
Patchell et al.,
1998 [52]
95 total
49 S+R
46 S
57 NSCLC
9 Breast
29 Other
CNS
recurrence
rate
S+R (48 wk)
vs. S (43 wk),
p=0.39
10% S+R
46% S
P<0.001
14% S+R
37% S
P<0.01
Single brain metastasis.
Overall CNS recurrence rate (primary
endpoint) significantly less in R-treated
patients (18% S+R vs. 70% S, p<0.001).
Decreased rate of neurological cause
of death in group receiving R (14% S
+R vs. 44% S, p=0.003)
Aoyama et al.,
2006 [49]
132 total
65 SRS+R
67 SRS
88 NSCLC
9 Breast
11 GI
10 Renal
14 Other
OS SRS+R
(7.5m) vs.
SRS (8 .0 m),
p=0.42
1-y rate
11% SRS
+R
38% SRS
P=0.002
1-y rate
42% SRS+R
64% SRS
P=0.003
1-4 brain metastases.
Overall CNS recurrence rate at 1-y:
47% SRS+R
76% SRS
P<0.001
Salvage treatment required:
15% SRS+R
43% SRS
P<0.001
Muacevic et al.,
2008 [44]
64 total
31 SRS
33 S+R
22 NSCLC
10 GU
11 Breast
9 Mel.
4 GI
8 Other
OS 9.5 m S+R
10.3 m SRS
P=0.8
1-y rate
3% SRS
18% S+R
P=0.06
1-y rate
26% SRS
3% S+R
P=0.04
Single, surgically accessible brain
metastasis.
Study stopped early due to poor
accrual.
Chang EL et al.,
2009 [50]
58
28 SRS+R
30 SRS
32 NSCLC
8 Breast
7 Mel.
4 Renal
7 Other
HVLT at 4 m
vs. baseline
SRS+R (5.7
m) vs. SRS
(15.2m),
p=0.003
1-y rate
0% SRS+R
33% SRS
P=0.01
1-y rate
27% SRS+R
55% SRS
P=0.02
Up to 3 brain metastases.
Decline in function at 4 m (primary
endpoint):
48% SRS+R
24% SRS
P=0.04
Study accrual stopped early due to
achieving primary endpoint.
Kocher et al.,
2011 [51]
359 total
SRS 100
SRS+R 99
S 79
S+R 81
190 NSCLC
29 Renal
42 Breast
18 Mel.
30 Colon
50 Other
Duration of
functional
independenc
e
(measured as
deterioration
of WHO PS to
>2)
WBRT (10.7
m) vs. No
WBRT (10.9
m), p=0.89
2-y rate
S – 59%
S+R – 27%
(p < 0.001)
SRS – 31%
SRS+R –
19%
(p = 0.040)
2-y rate
S – 42%
S+R – 23%
(p = 0.008)
SRS – 48%
SRS+R –
33%
(p = 0.023)
1-3 brain metastasis eligible. Either
stable extracranial disease for 3
months or no extracranial metastases.
Median Survival with WHO PS ≤2
(primary endpoint) 9.5m WBRT vs. 10.0
m no WBRT, p=0.709
Overall rate of CNS progression at 6
and 24 m: 15.2% and 31.4% WBRT vs.
39.7 and 54% no WBRT, p<0.0001
Neurological cause of death 25%
WBRT vs. 43% no WBRT, p=NR
Table 5. Randomized trials of adjuvant WBRT with surgery or stereotactic radiosurgery for brain metastases
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one patient in each group had melanoma. The CNS recurrence rate was 18% (9/49) in those
receiving adjuvant WBRT. This contrasted sharply with a 70% (32/46) CNS recurrence rate in
the observation group (p<0.001). The median time-to-CNS recurrence was markedly pro‐
longed in those receiving adjuvant WBRT (220 weeks versus 26 weeks observation, p<0.001)
due to decreased recurrence rates both at resection sites (10% WBRT versus 46% observation,
p<0.001) and at distant sites within the brain (14% WBRT versus 37% observation, p<0.01).
There was no difference in median survival (49 weeks WBRT versus 43 weeks observation,
p=0.39) or in maintenance of independent function (maintenance of KPS >60%). A decreased
rate of neurologic cause of death was evident in the WBRT-treated group (14% WBRT versus
44% observation, p=0.003), although the determination of this was less objective than deter‐
mination of intracranial recurrence by imaging.
Another randomized trial tested adjuvant WBRT (30 Gy in 10 fractions) in conjunction with
SRS [49]. The study enrolled 132 patients with one-to-four metastases measuring less than 3
cm in maximal dimension. Sixty-five patients received SRS and WBRT; sixty-seven received
SRS alone. Two-thirds of those enrolled had NSCLC. The majority of the remainder had breast,
colon or renal primary sites. The primary endpoint was overall survival. The researchers
initially estimated that 89 evaluable patients per group would be required to detect a 30%
difference in median survival time. A planned interim analysis, performed after 122 patients
enrolled, led to early study termination. Four-to-five-fold more patients would have been
required to detect a significant difference in the primary endpoint.
Although underpowered to detect a survival advantage, a number of secondary endpoints
yielded significant results. CNS progression at 1 year was 47% in the combination therapy
group and 76% in the SRS monotherapy group (p<0.001). WBRT improved control at one year
for both SRS-treated sites (89% WBRT versus 72% without, p=0.002) and distant CNS sites (58%
WBRT versus 36% without, p=0.003). No differences were observed in median survival,
neurological cause of death, and acute or late neurological toxicity. Rates of systemic functional
preservation (assessed by KPS), neurological preservation, and neurocognitive preservation
(assessed by the Mini-Mental Status Examination, MMSE) were also not different.
A third trial randomized patients with 1-3 brain metastases to either SRS or SRS combined
with adjuvant WBRT (30 Gy in 12 fractions) [50]. A novel endpoint for the study was chosen:
change in performance on the Hopkins Verbal Learning Test-Revised (HVLT) at 4 months after
primary therapy. The majority of enrolled patients were those with NSCLC primary tumors
(55%), with melanoma in the minority (12%). The study was stopped early after accrual of 58
patients (28 SRS+WBRT, 30 SRS) due to its achieving the primary endpoint. Patients treated
with the combination demonstrated a 52% decline in HVLT score at 4 months, versus a 24%
decline in those receiving SRS only (p=0.04). This difference persisted at 6 months. Significant
differences in performance on a panel of other neurocognitive tests were not detected. The
study was stopped early and may have therefore been underpowered to detect other important
differences in outcome. Decreased HVLT performance occurred despite decreased rates of
CNS progression at one year in the combination therapy group (SRS-treated sites: 0% SRS
+WBRT vs. 33% SRS, p=0.01; distant CNS: 27% vs. 55%, p=0.02). The authors also reported
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improved survival in the group treated with SRS alone (5.7 months SRS+WBRT vs. 15.2 months
SRS, p=0.003).
Patients who were treated only with SRS required salvage therapy for intracranial progression
in 87% of cases. Ten (33%) of the patients treated with SRS alone required craniotomy, ten
(33%) received salvage WBRT and six (20%) received salvage SRS. In the group treated with
SRS and adjuvant WBRT, two patients (7%) received salvage WBRT, and three (11%) pro‐
gressed intracranially, but received no salvage therapy.
This study provides convincing evidence that the addition of adjuvant WBRT to SRS therapy
for brain metastases impairs HVLT performance. This occurs despite a decreased rate of
intracranial progression in those receiving WBRT. Salvage therapy for intracranial progression
was required in the majority of patients treated with SRS alone, including salvage craniotomy
in one-third of the patients. The clinical significance of HVLT deterioration due to adjuvant
WBRT, vis a vis that of frequently needed salvage therapy for CNS disease was not addressed.
A fourth randomized trial assessing adjuvant WBRT enrolled patients with 1-3 brain meta‐
stases and stable or absent extracranial disease [51]. The majority of patients had NSCLC (53%);
only 5% were melanoma patients. Patients received SRS or surgery as primary therapy and
were then randomized to receive adjuvant WBRT (30 Gy in 10 fractions) or no additional
therapy. The composite primary endpoint was median overall survival in patients with KPS
of 0-2. In the intent-to-treat analysis, 180 patients were assigned to receive WBRT and 179 to
observation. At the end of the study, per protocol, 164 patients received WBRT and 166 patients
were on observation. Analysis was by intention-to-treat.
No differences were detected in the primary endpoint of survival with functional independ‐
ence (9.5 months WBRT versus 10.0 months observation, p=0.709) or median overall survival
(10.7 months WBRT versus 10.9 months observation, p=0.891). Intracranial recurrence rates
were markedly suppressed by adjuvant WBRT. Overall intracranial progression occurred in
48% of WBRT-treated patients and in 78% of the observation group (p<0.001). This translated
to improved progression-free survival (PFS) in the WBRT-treated group (4.6 months vs. 3.4
months observation, p=0.002). Two years after surgery, WBRT reduced the probability of
relapse at intial site from 59% (observation) to 27% (p<0.001) and at distant CNS sites from 42%
(observation) to 23% (p=0.008). Similarly, after SRS, WBRT reduced the probability of relapse
at SRS-treated site from 31% (observation) to 19% (p=0.040) and at distant CNS sites from 48%
(observation) to 33% (p=0.023). Neurological cause of death was suppressed by adjuvant
WBRT (28% WBRT versus 44% observation; p<0.002). Extracranial disease progression rates
at 24 months were identical (65% WBRT and 63% observation, p=0.73).
All four randomized trials showed decreased intracranial recurrence rates when adjuvant
WBRT was administered, both at the site of treatment and at distant sites within the brain.
Similar effects from adjuvant WBRT on distant CNS recurrence were reported by the trial of
Muacevic and co-workers, in which patients were randomized to surgery with adjuvant WBRT
versus SRS alone, discussed above [44]. The impact on the reduction in distant CNS recurrence
with the use of adjuvant WBRT is likely from the eradication of subclinical microscopic disease
present at the time of brain metastasis diagnosis. The effect of WBRT on CNS seeding from
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uncontrolled extracranial disease is unclear, but likely has a lesser effect. If seeding from
extracranial disease was a dominant mechanism leading to CNS failure, adjuvant WBRT
would not be predicted to decrease its occurrence.
No  trial  to  date  evaluating  the  omission  of  adjuvant  WBRT  after  local  therapy  has
demonstrated a survival benefit to WBRT. The study by Chang and co-workers indicated
that the use of adjuvant WBRT after local therapy might be associated with a decrement
in  survival.  It  is  difficult  to  draw firm conclusions  about  these  data,  as  the  study  was
stopped early, was not powered to detect a survival benefit, and contradicted the surviv‐
al results of the other four larger randomized studies presented above. This includes the
study by Aoyama and co-workers  [50],  which evaluated overall  survival  as  its  primary
endpoint  and  was  unable  to  detect  a  survival  difference  between  its  treatment  arms,
without  a  marked  increase  in  sample  size  to  over  800.  The  study  by  Kocher  and  co-
workers demonstrated an improvement in PFS associated with adjuvant WBRT [51]. This
study  excluded  patients  with  uncontrolled  or  progressive  primary  disease,  mitigating
extracranial disease burden as a competing risk for death
The studies presented here represent the best assessment of the efficacy of adjuvant WBRT
therapy in treatment of solid tumor brain metastases. This therapy is clearly able to decrease
intracranial recurrence rates, both at locally treated and distant sites within the CNS. The effect
of this therapy on survival and the relative benefits versus the cognitive effects of the therapy
are less clear. Melanoma patients formed a small fraction of the patients enrolled in these trials
and one might therefore question whether these results even apply in the melanoma setting.
To do so requires examination of the rather imperfect retrospective dataset regarding adjuvant
WBRT specifically in melanoma.
2.4.2. Adjuvant WBRT in melanoma patients
The randomized studies discussed above primarily enrolled patients diagnosed with NSCLC.
There have been no prospective studies evaluating the role of adjuvant WBRT specifically in
the melanoma patient population. Many retrospective studies have been reported; unsurpris‐
ingly, these have indicated that adjuvant WBRT confers no survival benefit (see Tables 2, 4)
[8-10, 12, 19, 29, 31, 32, 34, 35, 38, 39, 41, 53]. Since most melanoma patients with brain lesions
present with active extracranial disease, any potential survival benefit due to adjuvant WBRT
after local CNS therapy is probably undermined: extracranial disease serves as a competing
cause of death, diluting any study’s statistical power.
It is difficult to make firm conclusions based on the numerous melanoma case series on whether
adjuvant WBRT actually decreases the rate of intracranial recurrence after local therapy.
Selection and ascertainment biases are major concerns. Patients with clinically advanced
disease are often selected for more aggressive therapy. Groups receiving aggressive therapy
are likely to undergo more frequent and detailed surveillance for recurrence.
Several retrospective studies identify such biases. In the study of Buchsbaum and co-workers
a paradoxically higher rate of CNS recurrence (49%) was identified in patients having received
combined local CNS lesion therapy and adjuvant WBRT versus local therapy alone (20%) [10].
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Follow-up scans were more frequent in the combined therapy group, possibly explaining the
increased detection of progression and therefore higher documented recurrence rates.
Samlowski and co-workers indicated that patients having received combined SRS and
adjuvant WBRT had a higher mean number of CNS lesions at presentation than those selected
for SRS alone [37]. Not surprisingly, more aggressive upfront therapy is apparently adminis‐
tered to patients with a greater initial disease burden.
Another study reported that patients receiving SRS with WBRT had 0% 1-year actuarial control
within the CNS versus 60% for those treated with SRS alone (p=0.0005), strongly suggesting
selection bias [38]. Those patients with initially more advanced disease were more likely to be
treated with the combined modality technique. Advanced disease was found as a strong
predictor for poorer outcomes. Therefore local control rates were likely confounded by the
level of disease burden at presentation and not necessarily by the choice of treatment modality.
Other studies indicate similar paradoxical results in patients treated with adjuvant WBRT.
Wronski and Arbit reported an increased risk of CNS recurrence (56%) in patients treated with
surgery and WBRT versus 46% in those treated with surgery alone [9]. Another study reported
a 20% failure rate at SRS-treated sites in patients receiving adjuvant WBRT versus 0% in those
treated with SRS alone [33]. Perhaps indicative of a possible beneficial effect from adjuvant
WBRT, failure at distant sites within the CNS was only 23% in the combination therapy group
versus 44% in those treated with SRS alone. Those failing at the local site after combined
modality treatment had larger initial volumes of disease compared with those treated with
SRS alone. The additional fractionated dose contributed from WBRT at the site of failure may
not have adequately addressed the increased tumor burden initially present. This was likely
a significant confounder in local control outcomes.
Several studies concluded that WBRT does not significantly impact CNS recurrence rates. In
one study of 333 melanoma patients, WBRT before or after SRS did not alter the intracranial
recurrence rates [31]. The same study also showed that patient survival was significantly
shorter with WBRT (4.5 months) compared to SRS alone (6.4 months, p=0.05). Again, selection
bias for patients with more lesions or more aggressive disease could explain this result. Radbill
et al. reported that adjuvant WBRT did not decrease the rate of failure at non-SRS-treated sites
in the CNS (p=0.13) [35]. However, the number of patients treated with adjuvant WBRT (13%)
was potentially too small to detect a benefit. Mingione et al., studying 45 melanoma patients,
of whom 16 received adjuvant WBRT, concluded that WBRT had no impact on outcomes [32].
Yu et al. also found that adjuvant WBRT did not decrease distant CNS recurrence; this
conclusion was again limited by the small proportion of WBRT-treated patients (32/122
patients; 32%) [41].
Three studies have suggested a benefit from WBRT in preventing CNS recurrence in the
melanoma population. One retrospective study of 35 melanoma patients undergoing resection
of a single brain metastasis at a single institution from 1972 to 1987 documented a CNS
recurrence rate of 37% in those treated with adjuvant WBRT, versus 69% in those not receiving
this therapy (Table 2) [53]. Median time to CNS relapse was 26.6 months in the group receiving
adjuvant WBRT, as compared to 5.7 months in those not receiving such therapy (p<0.05).
Survival was predicted by the extracranial disease status, rather than receipt of adjuvant
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WBRT. Death due to neurological causes was more common in the group that did not receive
WBRT (24% WBRT versus 85% observation, p<0.01).
Another study during approximately the same time period (1979-1991) examined adjuvant
WBRT after surgery in patients with a solitary CNS metastasis from melanoma (Table 2) [54].
Patients had no active extracranial disease and underwent resection of a single metastasis. Of
the 34 subjects, 22 received WBRT. Median survival was improved in the combination therapy
group (18 months versus 6 months with surgery alone, p=0.002), but CNS relapse rates were
similar (30% surgery+WBRT vs. 22% surgery only; p=0.65). This study evaluated a highly
selected patient group. This study and that of Hagen also suffer from being older studies, with
more limited CNS imaging capabilities [53]. Nevertheless, the results tend to echo those of
Patchell’s randomized trial, suggesting a decreased CNS recurrence rate in CNS melanoma
patients treated with adjuvant WBRT after local therapy [52].
Another report reviewed a single institution’s experience with SRS in the treatment of 41
patients with radioresistant tumors, including 23 with melanoma [19]. Adjuvant WBRT
improved local control (100% control with SRS and WBRT versus 85% with SRS alone at 6
months) and distant brain failure rates (17% failure with SRS and WBRT versus 64% failure
with SRS alone). As might be predicted, adjuvant WBRT did not affect overall survival.
In summary, retrospective case series in melanoma indicate that adjuvant WBRT does not
convey an overall survival benefit. This is consistent with the results of the randomized trials
of WBRT primarily conducted in non-melanoma brain metastases. It is therefore reasonable
to conclude that the addition of adjuvant WBRT does not improve the overall survival of the
majority of melanoma patients with brain metastases.
As regards the effect of adjuvant WBRT on the prevention of CNS recurrence in melanoma,
this collection of retrospective studies provides conflicting data. Some have shown no effect,
others have shown decreased intracranial recurrence rates with the addition of WBRT, and
still others have indicated that WBRT is associated with increased recurrence rates. Biases in
treatment selection and ascertainment are strong confounders in many of the studies.
An ongoing randomized phase 3 trial is currently accruing for the comparison of distant
intracranial control with the addition of adjuvant WBRT to observation following surgery and/
or SRS in melanoma patients with 1-3 brain lesions (NCT01503827) [55]. Secondary endpoints
will include the effects on OS, QOL, and NCF. This prospective, randomized, melanoma-
specific trial will hopefully reconcile the contradictory observations reported in the retrospec‐
tive studies discussed above. With improving systemic therapy, including agents able to
penetrate the CNS at clinically relevant concentrations, even this randomized trial may not be
able to answer its major questions about adjuvant WBRT in melanoma patient.
Salvage SRS: An alternative to WBRT?
An alternative strategy to managing CNS metastases involves the use of “salvage” SRS. After
patients receive initial local therapy with SRS alone, WBRT is omitted to spare normal brain
tissues from unnecessary radiation doses and avoid potential adverse neurocognitive effects.
Patients undergo CNS imaging at planned intervals or if symptoms suggest progression. SRS
is then used to treat new lesions.
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This  strategy  has  not  yet  been  tested  in  a  randomized  trial  for  patients  with  brain
metastases  from  melanoma.  There  are  limited  data  that  have  included  melanoma  pa‐
tients in the prospective evaluation of this treatment paradigm. For example, one prospec‐
tive study assessed SRS as a single treatment modality in 41 patients with no more than
4  brain  metastases  [56].  Seven  (16%)  of  the  patients  had  melanoma  primary  tumors.
Twenty-three  of  the  enrolled  patients  (56%)  experienced  intracranial  progression.  Nine
received  salvage  treatment  with  additional  SRS  and  one  with  surgery  and  WBRT  for
persistent  tumor.  Eleven patients  were  treated with  salvage  WBRT due  to  an  excessive
number of new CNS lesions and two patients received non-radiotherapy palliative therapy.
Intracranial recurrences were common in the absence of upfront WBRT; less than half of
recurring patients (9/23) were eligible for salvage SRS therapy due to excessive number of
new lesions, limited life expectancy or decreased performance status.
Data  from  a  large,  multi-institutional,  retrospective  study  of  569  patients  (16%  with
melanoma) support the feasibility of salvage SRS in replacement of upfront WBRT [57]. Of
268 patients treated initially with SRS alone, 98 received salvage therapy for CNS recur‐
rence.  Sixty-three (64%) of  those needing salvage therapy received WBRT as part  of  the
salvage  regimen  (which  included  SRS  and/or  surgery)  and  forty-seven  (48%)  received
WBRT as the sole salvage therapy.
One retrospective study examined 45 patients (20 with melanoma, 44%) receiving SRS as
salvage therapy [58]. Excellent local control at treated sites was achieved (92.4% at 52 weeks).
Patients who received upfront WBRT were significantly less likely to require salvage therapy
(p=0.008), although no survival benefit was reported.
A CNS metastasis management strategy in which SRS is used as sole initial therapy warrants
continued evaluation, particularly for patients diagnosed with melanoma. The existing studies
of this approach suggest that intracranial recurrence rates remain high with the omission of
WBRT. Although salvage therapy with SRS may be planned initially, a large fraction of patients
will require WBRT in the salvage setting to treat macroscopic recurrences, when WBRT is likely
to be least effective
2.4.3. Neurocognitive effects of WBRT
A major argument against  the use of  adjuvant WBRT relates to its  impact  on NCF and
higher executive neurologic functions,  including learning,  memory,  calculation,  and task
planning. A variety of standardized neuropsychological tests measure global NCF, such as
the MMSE. NCF impairment has a direct impact on overall QOL, affecting patients’ ability
to  carry  out  activities  of  daily  living,  medical  treatment  compliance,  and  higher  order
planning and function [59].
One widely cited retrospective study examined patients treated at a single center for brain
metastasis by either WBRT alone (n=370) or surgical metastectomy combined with WBRT
(n=118) [60]. Radiation-associated dementia was reported at a rate of 1.9 (n=7) and 5.1% (n=5),
respectively. Cases were defined as those patients treated for brain metastases with WBRT
without evident CNS recurrence who subsequently developed “…a progressive dementing
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illness.” Neither baseline neurocognitive data information for the identified cases nor infor‐
mation regarding the source populations was provided. Among the 12 cases identified, a
variety of radiation dose and fractionation schemes were employed. The authors suggested
that the incidence of radiation-related leukoencephalopathy might have been underestimated
due to lack of sensitive tools for identifying neurocognitive dysfunction. Baseline neurocog‐
nitive dysfunction in patients with primary or secondary brain malignancy, however, is
present in as many as 90% of patients prior to treatment [61] due to the general debility of
patients with metastatic cancer, the neurocognitive effects of systemic chemotherapy and
supportive therapies, and the age of the patients. Thus, the results of this relatively old study
do not provide a clear picture of neurocognitive dysfunction associated with radiotherapeutic
treatment of brain metastases.
Fairly good evidence shows that radiation therapy of the brain leads to neurocognitive
dysfunction, which in some cases can be severe. A variety of patient-related factors play a role
in the development of risk for developing radiation-associated neurocognitive dysfunction.
These include patient age (children or those more than 50 years of age), other therapies received
(chemotherapy and/or anti-convulsants), and length of survival post radiation therapy (as seen
in survivors diagnosed with more favorable and indolent diseases, e.g., low-grade glioma)
[62-68]. Factors related to radiation therapy delivery include total dose received, dose per
fraction, and amount of cerebral volume irradiated [68-71].
More rigorous prospective assessments suggest that the neurocognitive impact of WBRT may
be modest. Data from the study of primary brain tumor patients, in which extracranial disease
and its treatment are not factors, may be relevant. For example, one study examined the dose-
dependency of radiotherapy-associated neurocognitive dysfunction in patients treated for
primary brain tumors [71]. Neuropsychological testing was undertaken up to 12 months after
completion of radiotherapy. No dysfunction was observed in patients receiving up to 30 Gy,
a typical dose used for adjuvant WBRT. Fraction size was not reported.
Another setting to examine the effects of WBRT is in diseases for which PCI is of proven benefit,
such as SCLC. In two large studies evaluating the role of PCI for good responders with SCLC,
there was no difference in NCF between those randomized to receive WBRT or not (24 Gy in
12 fractions-36 Gy in 18 fractions) [47, 48]. In the study by Gregor et al., both groups of patients
demonstrated baseline neurocognitive impairment versus normal controls, likely reflecting
effects of prior treatment. Among those without baseline impairment, impairment in cognitive
test performance was evident at 6 months and 1 year, but no obvious differences were seen
when comparing PCI-treated and –untreated patients. The authors did not, however, describe
rigorous statistical assessment of the longitudinal neurocognitive testing data [48].
Another prospective, non-randomized study showed no difference in cognitive function after
30-40 Gy of radiation therapy with 2-34 months of follow-up [72]. Again, a high degree of pre-
existing neurocognitive deficit was already present. This may have been attributable to
chemotherapy given prior to radiation therapy.
A non-randomized, prospective study of PCI was undertaken in NSCLC patients [73]. Seventy-
five patients received induction radiochemotherapy for locally advanced NSCLC. Forty-seven
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received PCI (30 Gy over 3 weeks), while twenty-eight others did not. PCI reduced the overall
rate of brain relapse from 54% to 13% at 3-4 years. In fifteen long-term survivors (10 PCI, 5
without PCI), no significant differences were noted in a battery of neuropsychological tests
undertaken at a median of 47 (PCI) and 70 (no PCI) months.
A study recently presented short term follow-up of longitudinal NCF in patients having
received PCI (small cell lung cancer; n=13), therapeutic cranial irradiation (TCI; brain meta‐
stases; n=16) or non-cranial irradiation (control: breast cancer; n=15) [74]. NCF was assessed
prior to and during radiation treatment and 6-8 weeks after its completion. At 6-8 weeks after
treatment, only verbal memory scores were lower in patients receiving cranial irradiation
versus controls. Visual memory and attention were not affected. Pre-treatment verbal memory
performance score was the major predictor of post-treatment outcome in univariate analysis,
with a lesser contribution attributable to cranial irradiation. The data from this admittedly
small study suggest that WBRT can have a negative impact on verbal memory, although other
factors contributing to the baseline status seem dominant.
Aoyama and co-workers conducted a randomized trial of SRS with or without WBRT,
discussed in detail above [75]. Baseline and follow-up MMSE scores were available for 110 and
92 of the 132 patients enrolled in the trial, respectively. Baseline MMSE scores were predicted
by patient age, performance status, tumoral edema and total tumor volume, but not by the
initial number of tumors.
Deterioration in MMSE occurred in equal proportions of each group (14/36 SRS + WBRT versus
12/46 SRS alone, p=0.21). Average time-to-deterioration was longer in the combined therapy
group (13.6 months versus 6.8 months SRS alone, p=0.05). In the 14 members of the combined
therapy group, the adjudged cause of deterioration was brain tumor progression in 3, toxic
effects of radiotherapy in 5 and indeterminate in 6; in the group treated only with SRS, MMSE
deterioration was due to brain tumor progression in 11 and indeterminate in 1 (combined vs.
SRS, p<0.0001). The temporal trends in NCF between the two arms suggest that SRS-related
cognitive decline may be associated with tumor recurrence, which may or may not be rever‐
sible with salvage therapy. Later dysfunction with WBRT is more variable in cause. Some may
be attributable to CNS tumor recurrence, but other cases being attributable to late effects of
radiation on normal brain tissue. Such treatment-associated damage would not be amenable
to corrective therapy with further tumor-specific therapy.
The study of Chang and co-workers, discussed earlier, prospectively addressed NCF in the
setting of adjuvant WBRT [50]. This study is notable in that the score on a specific neurocog‐
nitive test, HVLT, was the primary endpoint. Patients receiving adjuvant WBRT experienced
greater rates of decline in their HVLT performance than those treated with SRS alone, despite
decreased intracranial progression in the WBRT-treated patients.
The HVLT tests basic verbal learning capacity and is proposed as a screening test for mild
dementia [76, 77]. The HVLT may have somewhat greater sensitivity for mild dementia than
the MMSE, as well some logistical advantages [78]. In isolation, however, results from the
HVLT must be judged cautiously, as it does not assess other more complex neurocognitive
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functions [79]. In studies of patients with brain metastases, the test is part of a battery of
administered tests intended to develop a general overview of neurocognitive function [80, 81].
In the Chang study, a battery of neurocognitive function tests was administered, along with
HVLT. Differences in performance on these other tests were not different between the two
groups. The authors cautioned that the wide confidence intervals in the results of non-HVLT
tests did not exclude a difference between the two test groups, but they also did not demon‐
strate a specific difference between the groups.
Studies of the effects of brain radiotherapy presented here vary in quality. They do not however
give a clear picture suggesting severe adverse consequences of brain radiotherapy. Adverse
effects are certainly identified in several studies, although their clinical significance is not
certain and its cause is not clearly attributable to CNS radiotherapy. Intuitively, radiation
therapy in and of itself is not beneficial for the nervous system. In the setting of brain metastasis
treatment, however, the adverse effects of radiation therapy must be balanced against those
of CNS tumor recurrence.
2.4.4. Neurocognitive effects of brain tumor progression
While little melanoma-specific data are available, the primary brain tumor literature reveals
that there are significant negative cognitive effects from tumor progression. This literature is
particularly useful, as cognitive deterioration in primary brain tumor patients is due entirely
to incracranial disease and CNS treatment effects, as opposed to extracranial disease progres‐
sion. Deterioration in MMSE was a strong predictor of impending intracranial tumor progres‐
sion in a study of 1,244 glioma patients [82]. A change in MMSE score was seen even prior to
radiographic progression. Decreased MMSE score also strongly correlated with performance
status deterioration.
Another study in 445 brain metastasis patients (25 with melanoma) compared the drop in
MMSE score before and after treatment with WBRT [83, 84]. The study was designed to assess
the effect of the radiation fractionation schedules on survival, for which no effect was found.
Tumor control was the primary factor in determining MMSE scores at 3 months. A 6.2 point
drop (out of 30 possible) was seen in those with radiographic evidence of progression,
compared to a 0.5 point drop in those with controlled tumors. In multivariate analysis, control
of brain metastases was the only factor affecting MMSE score.
Another prospective brain metastasis study assessed a novel radiosensitizing agent combined
with WBRT [85]. A detailed neurocognitive battery assessed NCF before and after therapy.
Patients in the control arm, receiving WBRT alone, were subdivided into “good responders”
(at least a 45% reduction in tumor size) and “poor responders” (less than a 45% reduction).
Good responders had better NCF preservation rate, as well as a modest survival advantage
(median survival 300 days versus 240 days; p=0.03).
These studies indicate that CNS tumor progression has adverse effects on neurocognitive
status  and  QOL  (reflected  by  performance  status  deterioration).  While  not  melanoma-
specific, there is no reason to believe that CNS progression of melanoma tumors would be
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any less  adverse.  These  adverse  effects  of  tumor  progression  must  be  balanced against
those of adjuvant WBRT.
2.4.5. WBRT in advanced CNS melanoma
In some patients, disease in the CNS cannot reasonably be controlled using local treatment of
brain metastases with surgery or SRS. At some point, lesion number becomes excessive, or
lesions are present in locations that are not amenable to local treatment. Alternatively, a
patient’s extracranial disease may be so extensive that it is likely to be life-limiting, and the
goal of CNS disease treatment is primarily symptom palliation. WBRT is often used in this
circumstance, with the twin goals of improving survival and providing symptoms palliation.
No randomized, prospective studies are available to quantitate the benefit of WBRT, especially
when compared to supportive care alone. A number of large retrospective case series have
examined the questions specifically of survival, although these suffer from heterogeneous
patient populations. In the study of Sampson and co-workers, 205 melanoma patients with
brain metastases received systemic palliative chemotherapy, with median OS of 39 days,
versus 120 days among the 180 patients treated only with whole brain radiotherapy (p=0.0006)
[8]. Receipt of radiotherapy treatment was statistically significant in the multivariate analysis
of another large retrospective study, with radiotherapy demonstrating median OS of 3.6
months, versus 1.3 months for those treated with corticosteroids alone (HR=0.38; p<0.001). In
the study of Raizer and co-workers, 83 patients received no specific therapy for brain meta‐
stases, vesus 100 receiving WBRT alone [13]. Median OS was 2.0 and 4.0 months, respectively.
The statistical significance of this difference was not reported.
The study of Fife and co-workers examined patients treated at a single center in Australia in
the 1952-2000 date range [12]. For the 1985-2000 cohort, 210 patients received supportive care,
versus 236 receiving radiotherapy alone. Median OS was 2.1 and 3.4 months in these two
groups; in multi-variate Cox regression analysis, radiotherapy was associated with a decreased
hazard ratio for death (HR-0.851; p=0.111). This may not have achieved statistical significance
due to the heterogeneity of the patients in these two groups. In addition to treatment modality,
other significant factors associated with survival were the presence of concurrent metastases
at diagnosis, older age, and a longer time from initial melanoma diagnosis.
An older retrospective study identified 60 melanoma patients with cerebral melanoma
metastases that were enrolled in two Radiation Therapy Oncology Group (RTOG) studies [86].
The study sought to determine the effects of WBRT on performance status, neurologic function,
and neurologic symptoms. In the analysis, this study demonstrated that WBRT provided
improvement of neurologic symptoms (including headache, motor loss, convulsion) in 76% of
patients. Median survival in this uncontrolled report was 10-14 weeks, although the baseline
clinical characteristics of the study population were quite variable.
Another retrospective study identified 87 patients who had received WBRT, of whom 46 (53%)
had 3 or more metastases [87]. The majority of patients were already receiving dexamethasone
before initiating radiation, and therefore it was difficult to isolate the effects of WBRT, since
CNS signs and symptoms can be alleviated by corticosteroid treatment. The fraction of patients
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discontinuing corticosteroids due to symptom improvement served as a surrogate marker for
palliative effects of WBRT. Upon completion of WBRT, 52% of all patients and 48% of symp‐
tomatic patients discontinued steroids. The same study demonstrated a small measurable
response in tumor size following WBRT. Out of 87 patients, 65 had measurable disease at
baseline; only 28 had at least one follow-up MRI scan to assess response. This may reflect a
bias favoring follow-up scans being undertaken in those with responding disease. In these 28
patients at a median follow-up of 7 weeks, 75 tumors showed a median reduction in tumor
size of 17%. The median OS of all patients evaluated in this study was 19 weeks. The median
OS for patients who had undergone surgical resection prior to WBRT (22 patients) was 45
weeks, versus 16 weeks for those who did not undergo surgical resection (p<0.0001). Absence
of extracranial disease (in 14 patients) was associated with higher median OS of 54 weeks,
compared to 17 weeks in patients who had extracranial disease (p<0.0001).
Two prospective studies have combined WBRT with either temozolomide or fotemustine in
melanoma patients with brain metastases [88, 89]. With temozolomide in a phase 2 study of
31 patients, only 3 (10%) demonstrated a response in the CNS, with median PFS in the CNS
and OS of 2 and 6 months, respectively. In the phase 3 study of the combination with fote‐
mustine, objective response rate (ORR) was 10% with median time-to-CNS-progression of 56
days and median OS of 105 days. These studies provide estimates of the clinical effect of WBRT,
even though the relative contributions of WBRT and chemotherapy drug cannot be quanti‐
tated.
The use of WBRT in a patient with advanced CNS melanoma probably yields a modest
survival benefit over supportive care alone. Symptom palliation is also probably a benefit
of this therapy. There are many holes in the WBRT data set, many of which will never be
answered definitively as melanoma treatment evolves. WBRT as a monotherapy has several
signifcicant disadvantages, including its modest benefit at best, inability to undertake re-
treatment,  and  lack  of  effect  on  extracranial  disease.  These  limitations  will  likely  be
overcome only with the design of systemic therapy regimens, to be administered concur‐
rently with, or in lieu of, WBRT.
2.5. Systemic therapy
Until the recent approvals in 2011 of ipilimumab [90, 91] and vemurafenib [92], no therapy
tested in a randomized trial demonstrated an improvement in overall survival for metastatic
melanoma patients. Dacarbazine had been the standard first-line systemic treatment since it
was approved in the United States in 1975. Metastatic melanoma patients with intracranial or
meningeal metastases were generally excluded from clinical trial participation for three
reasons: 1) brain metastases were thought to portend a poor prognosis; 2) systemic therapies
that were tested were not very effective in intracranial disease; and 3) it was presumed that
most agents would not cross the blood-brain barrier. In this section, we will cover efforts to
use chemotherapy, molecularly-targeted therapy, and immunotherapy for the management
of melanoma brain metastases (Table 6) [88, 89, 93-99].
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2.5.1. Chemotherapy
Several chemotherapeutic regimens failed to demonstrate benefit in melanoma brain meta‐
stasis, including regimens containing platinum-based compounds, dacarbazine, etoposide,
and others [87, 100-109]. This may be largely due to the low efficacy of many of the tested
agents in melanoma generally. It is probably unreasonable to expect agents with limited
activity against extracranial disease to have activity in the CNS, with the added barrier of CNS
penetration. Three chemotherapy agents with defined CNS activity in non-melanoma neo‐
plastic settings, namely temozolomide, thalidomide, and fotemustine have been investigated
in some detail in melanoma [110, 111].
Temozolomide is metabolized to the same active metabolite as dacarbazine. It is orally
bioavailable and penetrates the blood-brain barrier at clinically significant concentrations
[111]. The drug is approved for the treatment of primary brain tumors, confirming its clinically
significant penetration of the CNS. Since temozolomide is as effective as dacarbazine in
treatment of metastatic melanoma and yields similar patient survival [112], several clinical
trials evaluated its efficacy in melanoma patients with brain metastases.
A multicenter, open label, single-arm phase 2 study aimed to determine the efficacy and safety
(both as primary endpoints) of temozolomide in metastatic melanoma patients who had
developed brain metastasis [93]. The study enrolled 151 patients, comprising of 117 chemo‐
therapy-naïve and 34 previously treated. The clinical condition of the enrollees did not require
immediate surgery or radiation therapy, justifying chemotherapy as the sole therapy.
For chemotherapy-naïve patients, eight patients (7%) achieved response, including one
complete (CR) and seven partial responses (PR); 34 patients (29%) achieved stable disease (SD)
in brain lesions for at least 4 weeks. Median OS was 3.5 months. In previously treated patients,
1 patient (3%) achieved PR, 6 (18%) had SD, and the median OS was 2.2 months. Notably, 25%
of the chemotherapy-naïve and 21% of previously treated patients had extensive intracranial
disease, defined as more than 4 radiologically evident brain lesions. The authors concluded
that further evaluation was warranted, particularly in combination with other treatment
modalities, but activity as a single agent in this setting was limited.
The combination of temozolomide and WBRT has been evaluated. A prospective phase 2 trial
evaluated the combination in patients with CNS melanoma [88]. In 31 evaluable patients,
temozolomide and WBRT combination yielded an overall ORR of 9.7%, comprising of one CR
in the CNS lasting 4.5 months and two PR in the CNS lasting 2 months and 7 months. Although
the combination of temozolomide and WBRT could be safely administered, its efficacy was
limited.
Thalidomide, an anti-angiogenic agent crossing the blood-brain barrier, has been tested in
combination with temozolomide to treat melanoma patients with brain metastases. In a phase
2 study, the combination of temozolomide and thalidomide was tested in chemotherapy-naïve
patients [96]. The primary endpoint was ORR in the brain assessed every 8 weeks. Of the 26
patients treated, 16 patients were symptomatic and 25 had extracranial metastases. Treatment-
associated toxicity, especially hemorrhage and thromboembolism was a problem: eleven
patients discontinued treatment before completing one cycle of treatment due to intracranial
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hemorrhage (n=7), pulmonary embolism (n=2), deep vein thrombosis (n=1), and grade 3 rash
(n=1). Of 15 evaluable patients, 3 (12% of the intent-to-treat population) achieved CR or PR,
while 7 patients had minor response or SD in the brain. Of the 10 patients who derived benefit,
however, 5 patients progressed at extracranial sites. Overall OS was 5 months in all 26 patients,
while it was 6 months in the 15 evaluable patients. Given the limited efficacy and the toxicity
associated with the temozolomide/thalidomide combination, its use in melanoma is not
warranted, outside the setting of a clinical trial.
Temozolomide has also been evaluated in the adjuvant setting. A multicenter phase 3 study
compared temozolomide to dacarbazine in the time to develop CNS metastasis [94]. The study
randomized 150 patients to receive either oral temozolomide or intravenous dacarbazine in
combination with cisplatin and interleukin-2. Compared to dacarbazine, temozolomide
reduced the 1-year CNS failure from 31.1% to 20.6%, but was not statistically significant
(p=0.22). The median OS was not different between the two arms. Even though temozolomide
penetrates the CNS, it did not delay incidence of CNS failure. Thus it appears that temozolo‐
mide may not be very effective in the adjuvant setting.
Fotemustine is a chloroethyl-nitrosurea approved in Europe for the treatment of metastatic
melanoma. Fotemustine demonstrates high CNS penetration; its efficacy in melanoma patients
with intracranial disease has been evaluated in three major studies. A French multicenter phase
2 study evaluated 153 metastatic melanoma patients for response to single-agent fotemustine
[97]. Previously treated patients were allowed in the study. Since fotemustine crosses the blood
brain barrier, patients with intracranial metastases were enrolled.
Out of the 153 evaluable patients, 36 (23.5%) had cerebral metastasis as the dominant disease
site. In patients with cerebral metastases, the drug yielded an ORR of 25% in the CNS, similar
to the 24.2% ORR observed in extracranial disease. The median OS of all patients was 85 weeks,
but survival of the brain metastases patients was not reported. This study suggests that
fotemustine has activity in melanoma, including CNS metastases. The magnitude of the benefit
is similar in the CNS and at extracranial sites.
To confirm the observed activity, a phase 3 trial randomized 229 patients with metastatic
melanoma to receive either fotemustine or dacarbazine [113]. Dacarbazine is a useful and
interesting comparator in this study, as prior studies had failed to demonstrate any significant
activity in the CNS [100, 102, 104]. This study enrolled patients with and without pre-existing
brain metastases. Forty-three patients with brain metastases enrolled, of whom 22 received
fotemustine, while 21 patients received dacarbazine.
Among all patients, fotemustine yielded an ORR of 15% versus dacarbazine’s 7% (p=0.043).
The authors reported a trend to improved survival among fotemustine-treated patients, with
median OS of 7.3 months versus 5.6 months in the dacarbazine arm (p=0.067). In the brain
metastases sub-group, fotemustine yielded a 6% ORR, while dacarbazine produced no
responses. While myelosuppression was the most common adverse event observed in both
arms, fotemustine-induced myelosuppression was more frequent and severe. In the fotemus‐
tine arm, 71% (vs. 14% with dacarbazine) of patients experienced neutropenia, and 51% (vs.
5% with dacarbazine) of patients experienced grade 3- 4 neutropenia. Similarly, thrombocy‐
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topenia was observed in 94% of patients receiving fotemustine (vs. 57% with dacarbazine) and
grade 3- 4 occurred in 43% of patients (vs. 6% with dacarbazine).
The responses of patients who had brain metastases in this study were not as impressive as
previously reported in the phase 2 study discussed above, although this might be expected in
a more rigorous phase 3 study setting. Although not quite statistically significant, fotemustine
delayed the median time-to-develop first brain metastasis among those without pre-existing
brain lesions to 22.7 months, versus 7.2 months for patients treated with dacarbazine (p=0.059),
suggesting that fotemustine might have activity as an adjuvant treatment after surgical
management of CNS metastases. This has not been tested, as of 2012.
A multicenter phase 3 trial randomized 76 patients to receive fotemustine alone or in combi‐
nation with WBRT in brain metastasis patients and sought to determine the cerebral response
and time-to-cerebral-progression [89]. The primary endpoints of this study was to compare
the CNS ORR (CR+PR), CNS control rate (CR+PR+SD), and the time to CNS progression.
Compared to fotemustine alone, the combination did not significantly improve the ORR or the
control rate. The addition of WBRT, however, delayed CNS progression; it was 49 days (range
11–539 days) in the fotemustine-only arm and 56 days (range 19–348 days) in patients treated
with fotemustine and WBRT (Wilcoxon test, p=0.028). The combination did not, however,
significantly improve the clinical CNS control rate (after 7 weeks) or OS. In regards to safety,
myelosuppression was similar in both arms, but alopecia was much higher in the combination
arm (40% compared to 2.6% in the fotemustine-only arm).
2.5.2. Targeted agents
Approximately 40 to 50% of all melanomas harbor a mutation in BRAF [114]. Notably, 95% of
BRAF mutations are at the valine in the amino acid position 600, and over 90% of these are
substitutions to aspartic acid (depicted as V600E). In vitro, the V600E mutation causes a 500-
fold increase in the activity of B-Raf kinase; its expression is sufficient to cause tumor formation
by normal melanocytes injected into nude mice [114].
Vemurafenib, a small molecule inhibitor of the V600E-mutant, was approved in the United
States in 2011 for the treatment of metastatic melanoma in patients harboring the V600E
mutation [92]. Clinical trials leading up to its approval excluded patients who had active
intracranial disease. Thus, the efficacy of vemurafenib is not well studied in patients with pre-
existing intracranial disease.
A single-arm, open-label, pilot study was conducted in metastatic melanoma patients with the
V600E mutation and unresectable brain metastases, who failed previous treatments of
temozolomide and/or WBRT. Four patients, with extensive disease (3 to 10+ brain metastases),
were enrolled. At the time of the abstract presentation, the staging reports for two of the four
patients were available. The first patient had a confirmed PR in both intracranial and extrac‐
ranial lesions, while the second patient had minor responses in intracranial and extracranial
metastases. Although very limited data, vemurafenib exhibits preliminary evidence of activity
in melanoma patients with brain metastases who failed prior therapy [115]. Additional studies
are in progress to demonstrate efficacy of vemurafenib in melanoma patients with intracranial
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disease. For example, NCT01378975 is an open-label single-arm phase 2 study enrolling
metastatic melanoma patients with BRAF V600 and measurable brain metastases (sympto‐
matic or asymptomatic). Patients are enrolled regardless of prior systemic treatment history
for brain metastases (except for previous treatment with BRAF or MEK inhibitors). The high
response rate of patients harboring V600E mutations in melanoma (~50% vs. ~5% for dacar‐
bazine) suggests that vemurafenib, and potentially other BRAF-targeted therapies, might be
useful in post-surgical/SRS adjuvant therapy as an alternative to WBRT. This hypothesis
should be tested, especially if CNS activity is confirmed.
Dabrafenib is another potent and selective BRAF V600E inhibitor that inhibits growth of B-Raf
mutant melanoma and mutant B-Raf colorectal xenografts in mice [116]. In a phase 1 study,
184 patients with metatastic melanoma, untreated brain metastases, or other solid tumors
received dabrafenib [117]. Only three patients with wildtype B-Raf were evaluated, with no
evidence of benefit; such patients were subsequently excluded. The study included 156
metastatic melanoma patients, of whom 10 had pre-existing brain metastases. For patients with
intracranial disease due to melanoma, 9 out of the 10 patients had reductions in the size of their
brain lesions as well as their extracranial disease, with 4 of them achieving complete resolution
of the CNS lesions.
A phase 2 study specifically assessing the response to dabrafenib in melanoma patients with
intracranial disease harboring a V600E or V600K mutation was recently published [98]. The
study enrolled 172 patients, of whom 89 patients had not received previous local treatment for
brain metastases (cohort A) and 83 patients who progressed following previous local treatment
(cohort B). In cohort A, the overall intracranial response rate (OIRR), which is the primary
endpoint of this study, was 39.2% (29/74) in patients with the V600E mutation and 6.7% (1/15)
in patients with the V600K mutation. In cohort B, the OIRR was 30.8% (20/65) in patients with
the V600E mutation and 22.2% (4/18) in patients harboring the V600K mutation. These data
suggest clinical activity in melanoma brain metastases patients harboring the V600E mutation
and some activity in V600K patients, whether or not they received prior therapy for their brain
metastases.
Given the limited activity of agents available up to this time, such as temozolomide, findings
of CNS activity may not require formal confirmation in a phase 3 randomized trial. It is difficult
to imagine what the comparator agent of such a trial would be. However, a study of the
combination of either WBRT or SRS with concurrent B-Raf inhibitors (vemurafenib or dabra‐
fenib) or with B-Raf inhibitors following radiotherapy would be important in the development
of optimal therapy for patients with CNS metastases of melanoma.
2.5.3. Immunotherapy of melanoma in the central nervous system
Following the success, and subsequent FDA approval, of ipilimumab in the management of
metastatic melanoma [90, 91], several anecdotal case reports highlighted the activity of
ipilimumab in melanoma patients with brain metastases [118, 119]. For example, a retrospec‐
tive analysis assessing the activity of ipilimumab in melanoma patients with brain metastasis
who were enrolled in a phase 2 trial [120] identified 12 patients, of whom 2 achieved PR and
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3 had SD in brain metastases. The median OS of all 12 patients was 14 months (range was 2.7
to 56.4 months).
Another  retrospective  study  evaluated  the  outcome  of  77  patients  who  underwent
radiosurgery between 2002 and 2010 for melanoma brain metastases,  of whom 27 (35%)
received  ipilimumab  [121].  Ipilimumab–treated  patients  displayed  a  median  OS  of  21.3
months, versus 4.9 months for those not treated with ipilimumab. Even when adjusted for
performance status, ipilimumab treatment was associated with a higher survival probabil‐
ity  (HR  0.48,  p=0.03).  The  median  survival  of  ipilimumab-treated  patients  with  poor
prognosis (11/27 patients), who had Diagnosis-Specific Graded Prognostic Assessment (DS-
GPA; discussed in more detail below) score of 0-2 was 15.7 months, while those with better
prognosis (16/27 patients), DS-GPA score of 3-4 had a median survival of 25.2 months. The
survival of patients who received ipilimumab was similar whether they received ipilimu‐
mab before or after developing brain metastases.
To  determine  the  efficacy  of  ipilimumab  prospectively,  Margolin  and  colleagues  de‐
signed a  phase 2  study to  assess  the activity  of  ipilimumab in melanoma patients  with
brain metastasis [99].  The study segregated patients into two cohorts; cohort A included
51 patients  who were neurologically asymptomatic,  while  cohort  B included 21 patients
with symptoms requiring corticosteroids, which continued during the course of the study,
if necessary. The overall ORR in cohort A was 18% (9/51) and 5% (1/21) in cohort B. When
assessing response in brain lesions alone, the ORR in cohort A was 24% (12/51) and 10%
(2/21)  in  cohort  B.  The  ORR  of  extracranial  disease  was  similar  in  each  group  to  the
intracranial response: ORR was 27% (14/51) and 5% (1/21) in cohorts A and B, respective‐
ly. The median OS was 7 months for cohort A and 3.7 months in cohort B. Since the study
did not specifically address the cause of deaths for patients enrolled in the study, it is not
clear  whether  the  variation  in  OS  between  the  two  cohorts  was  due  to  progression  of
intracranial or extracranial disease, or additional complications associated with symptomat‐
ic intracranial disease.
A number of observations can be made from the results of this study: a) the response of
brain  lesions  was  similar  to  responses  in  extracranial  metastases;  and  b)  patients  with
asymptomatic  intracranial  disease,  not  on  corticosteroid  treatment,  tended  to  respond
better. The authors of the study present two hypotheses that may explain the difference in
response between the two cohorts: i) as suggested by survival data, patients with sympto‐
matic intracranial disease requiring corticosteroids have inherently poorer prognosis; or ii)
corticosteroids may potentially interfere with the effector lymphocyte activation induced
by ipilimumab. The authors did contend that corticosteroid use with ipilimumab did not
entirely abrogate its efficacy.
A single-arm phase 2 study conducted in seven Italian centers assessed the combination of
ipilimumab and fotemustine in patients with metastatic melanoma, including patients with
asymptomatic brain metastases [95]. The open-label, single-arm phase 2 study enrolled 86
metastatic melanoma patients, of whom 20 had brain metastases at baseline. The overall study
population disease control rate (defined as immune-related CR, PR, or SD) was 46.5% (40/86
patients). Similarly, ten of the brain metastasis patients (50%) achieved disease control. This
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study provides preliminary evidence that the combination of ipilimumab and fotemustine is
active in patients with metastatic melanoma, including those with intracranial disease. To
confirm the activity of the combination, a randomized phase 3 trial is planned and will compare
the activity of the combination versus fotemustine alone in patients with advanced melanoma
and brain metastases (NIBIT-M2; CA184-192).
Study Treatment Evaluable
Patients
Primary
Endpoint
Response Median Survival Comments
Agarwala et
al., 2004 [93]
TMZ 151 total
117 treatment
naive
35 pts prior
CTx
ORR in brain
and toxicity
No prior CTx:
ORR 7%
SD 29%
Prior CTx:
PR 3%
SD 18%
Treatment Naïve:
3.5m
Prior CTx:
2.2m
Margolin et
al., 2002 [88]
TMZ and WBRT 31 pts ORR CNS ORR 10%
(1 CR and 2 PR)
PFS 2m
OS 6m
Hwu et al.,
2005 [96]
TMZ +
Thalidomide
26 pts
16
symptomatic
25 extensive
extracranial
mets
ORR in CNS 15 evaluable pts
3 CR or PR (12%
by intent-to-
treat)
OS 5m
OS 6m (for
evaluable pts)
15 pts completed ≥ 1
cycle. 11 discontinued
before completing 1
cycle: 7 for intracranial
hemorrhage, 2 for
pulmonary embolism,
1 deep vein
thrombosis, and 1 for
Grade 3 rash
Chiarion-
Sileni et al.,
2011 [94]
CTI (TMZ +
Cisplatin + IL2)
vs.
CDI (DTIC +
Cisplatin + IL2
Phase 3
150 pts
118 evaluable
(57 in CTI and
61 in CDI)
Time to CNS
mets
CNS failure:
CTI -
24/57 pts
CDI
34/61 pts
P = 0.22
1y CNS failure
rate
CTI – 21%
CDI – 31%
PFS
CTI – 4.1m
CDI – 3.9m
P=0.90
OS
CTI – 8.4m
CDI – 8.7m
1y OS
CTI – 31%
CDI – 42%
Jacquillat et
al., 1990 [97]
Fotemustine 153 evaluable
pts; 36
(23.5%) had
CNS disease
ORR ORR 25% CNS NR for CNS pts. The overall ORR in all
pts was 24%
Mornex et
al., 2003 [89]
Arm A:
Fotemustine
vs.
Arm B:
Fotemustine +
WBRT
Phase 3
76 pts
Arm A: 39 pts
Arm B: 37 pts
CNS ORR on
day 50
CNS Control
Rate (CR+PR
+SD) on day 50
ORR
7.4% (arm A)
10.0% (arm B)
P = 0.73
Control Rate
30% (arm A)
47% (arm B)
OS
86 days (arm A)
105 days (arm B).
P = 0.561
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Study Treatment Evaluable
Patients
Primary
Endpoint
Response Median Survival Comments
Time to
objective CNS
progression
P = 0.19
Time to CNS
progression
49 days (arm A)
56 days (arm B)
P = 0.028
Long et al.,
2012 [98]
Dabrafenib 172 pts
Cohort A: no
prior CNS
therapy, 89
pts
Cohort B: Prior
CNS therapy,
83 pts
OIRR Cohort A
V600E 39%
V600K 6.7%
Cohort B
V600E 31%
V600K 22%
At 6 months,
Cohort A: 27%
Cohort B: 41%
Study limited to V600E
and V600K BRAF
mutated melanoma
Margolin et
al., 2012 [99]
Ipilimumab 72 pts
51 Cohort A
(no CNS
symptoms)
21 Cohort B
(CNS
symptoms
requiring
corticosteroids
)
Phase 2
DCR (CR, PR,
SD) at 12 wks
DCR
Cohort A
18%
Cohort B
5%
DCR in CNS
Cohort A – 24%
Cohort B – 10%
OS
Cohort A
7m
Cohort B
3.7m
Di Giacoma
et al., 2012
[95]
Fotemustine
+ Ipilimumab
86 pts total
20 CNS
disease at
baseline
Immune-
related DCR
(CR, PR, SD) at
24 weeks
DCR
Overall 46.5%
CNS 50%
CNS PFS 4.5m
CNS OS 13.4m
At 1-yr, 54% of
CNS pts alive
Out of the 10 brain
responses
5 PR or SD
5 CR
CNS: Central Nervous System; CR: Complete response; CTx: Chemotherapy; DC: Disease control; DCR: Disease control
rate; DTIC: Dacarbazine; NR: Not reported; OIRR: Overall intracranial response rate; ORR: Objective response rate; OS:
Overall survival; PFS: Progression-free survival; PR: Partial response; SD: Stable disease; TMZ: Temozolomide; WBRT:
Whole-brain radiation therapy
Table 6. Prospective trials of systemic therapy treatments for melanoma brain metastases
3. Risk stratification
Several systems estimate risk of recurrence and death in patients with brain metastases,
including some with melanoma-specific data (Table 7). Recursive Partitioning Analysis (RPA)
is one such system [122-124]. This combines age, performance status, and extracranial disease
status to assign a class from I to III that estimates survival. Its original intention was to stratify
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patients for enrollment in clinical trials. Its clinically available factors are useful to consider in
a discussion of brain metastasis patients.
RPA’s initial  description included 1200 patients,  200 of whom were affected by melano‐
ma. Histology and tissue of origin were significant prognostic factors, with melanoma being
unfavorable. The validity of RPA has since been confirmed in the melanoma subgroup [10,
19, 35, 42, 43].
While originally intended for stratification of patients in radiation therapy trials, RPA class
also stratifies risk in patients undergoing surgical metastectomy [125, 126]. In 2004, the RTOG
study enrolled 333 patients between 1996 and 2001, of whom 167 were assigned to WBRT and
SRS and 164 received WBRT alone [15]. Median survival was longer in patients with a single
brain metastasis for patients receiving WBRT+SRS combination compared to patients who only
received WBRT (6.5 months vs. 4.9 months, p=0.0393). This study shed light on a limitation of
RPA: it does not take into account the number of brain metastases present.
The Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) was developed by retro‐
spective analysis of 4,259 patients newly diagnosed with brain metastases [127]. In addition
to the factors in RPA, it includes number of brain metastases and the underlying disease giving
rise to brain metastases. In the melanoma subset, the analysis identified two significant
prognostic factors: performance status (represented by KPS) and number of radiologically
evident brain metastases. For KPS, a score of 90-100 is 2 points, 70-80 is 1 point, and less than
70 is 0 points. A single brain metastasis is 2 points, 2 to 3 metastasis is 1 point, and more than
3 metastases is 0 points. The DS-GPA score, calculated by adding the point values from a
patient’s KPS score and number of metastases, ranges from 0 (worst prognosis) to 4 (best
prognosis). Median OS for melanoma patients ranges from 3.4 months (GS-GPA score of 0 to
1.0) to 13.2 months (GS-GPA score of 3.5 to 4.0).
Several other systems have been developed for use in specific sub-populations. The Basic Score
for Brain Metastases (BS-BM) was developed by analyzing results from 110 SRS-treated
patients [128]. The system generates a score based on KPS, control of primary tumor site, and
extracranial disease status. Only 19 patients (17%) of the initial group of patients had mela‐
noma. The system has not yet been studied in melanoma patients specifically and focuses on
SRS treatment. Its applicability to other treatment modalities remains to be established.
The Score Index for Radiosurgery (SIR) was developed from the study of 65 SRS-treated pa‐
tients with brain metastases from a variety of primary tumor types [129]. SIR derives a score from
patient age, performance status, systemic disease status, maximum CNS lesion volume, and
number of CNS lesions. In the population initially studied, SIR was more accurate in predicting
survival than RPA. A retrospective study confirmed its utility in melanoma patients [38].
The Malignant Melanoma-Gamma Knife Radiosurgery score (MM-GKR) also assesses
outcomes in metastatic melanoma patients treated with SRS [23]. Scoring is based on perform‐
ance status, age, and CNS lesion location. The authors claim greater prognostic accuracy than
with either RPA or SIR, particularly in identifying patients with an especially poor prognosis.
The Prognostic Index (PI) score estimates prognosis in patients treated with palliative WBRT
[43]. Factors used in this system include number of extracranial metastatic sites, RPA class,
Management of Brain Metastasis in Melanoma Patients 33
CNS disease progression prior to WBRT, and the presence of meningeal disease. This system
is focused on those with extensive disease, not amenable to local therapy with SRS or surgery.
Median survival times predicted by studies of brain metastasis patients generally are similar
to those reported for melanoma patients with CNS involvement. With minor differences, the
systems described utilize similar and easily available data to arrive at their risk estimations.
RPA has probably been examined in the widest array of clinical trial settings. It also does not
seem to be specific to a given treatment modality. Its components are fairly simple to derive
from clinical parameters. It will therefore be used for further discussion.
System Prognostic Factors Prognostic Classification Median OS
(all tumor
types)
Median OS
(melanoma)
Comments References
RPA KPS, age, extra-
cranial disease
status, control of
primary disease site
Class I: KPS≥70, age<65 y., controlled
primary disease site, no extra-cranial
disease
Class II: Not Class I or III
Class III: KPS<70
Class I: 7.1 m
Class II: 4.2 m
Class III: 2.3 m
Class I: 6.5-10.5 m
Class II: 3.5-5.9 m
Class III: 1.8-2.5 m
Validated for
radiation therapy
and surgery.
Gaspar et al., 1997
[122]
Gaspar et al., 2000
[123]
Buchsbaum et al.,
2002 [10]
Lutterbach et al.,
2002 [124]
Harrison et al.,
2003 [42]
Morris et al., 2004
[43]
Radbill et al., 2004
[35]
Brown et al., 2002
[19]
PI Number of ECM,
RPA class (see
above), PD on
imaging prior to
WBRT, presence of
LM
Index= Number of ECM sites + (2 x RPA
class) + (2 if PD on pre-WBRT imaging) +
(4 if LM present)
NR Score To determine
outcome following
palliative WBRT.
Morris et al., 2004
[43]2-4
5-6
7-8
9-10
11+
138 d
80 d
42 d
18 d
15 d
SIR Age, KPS, extra-
cranial disease
status, volume of
largest CNS lesion,
number of CNS
lesions
Factor 0 1 2 Score Score Point values for
individual factors
are added to
derive score.
Intended for
assessment of
outcome after SRS.
Weltman et al.,
2000 [129]
Selek et al., 2004
[38]
Age ≥60 51-59 ≤50 0-3
4-7
8-10
2.9 m
7 m
31 m
≤6
"/>6
4 m
7 mKPS ≤50 60-70 ≥70
Systemic
disease
status
PD PR/SD CR
or
NED
Largest
Lesion
Volume
(cm3)
"/>13 5-13 <5
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System Prognostic Factors Prognostic Classification Median OS
(all tumor
types)
Median OS
(melanoma)
Comments References
# of CNS
lesions
≥3 2 2
MM-GKR Age, KPS, Adverse
CNS lesion locations
(brainstem,
posterior fossa,
nuclei, cerebellum)
Factor 0 1 1.5 2 NR Score Intended for
assessment of
outcome after SRS.
Gaudy-Marqueste
et al., 2006 [23]KPS <80 - - ≤80 0
1-2
≥2.5
7.1 m
5 m
2.2 m
Age ≤60 "/>60 - -
Adverse
Location
No - Yes -
BS-BM KPS, control of
primary tumor,
presence of ECM
Factor 0 1 Score NR Not validated in
melanoma,
although study
included 19
melanoma
patients out of 110
total (17%).
Score of 3 had OS
not reaching
median with 30 m
of follow-up.
Intended for
assessment of
outcome after SRS.
Lorenzoni et al.,
2004 [128]KPS 50-70 "/>70 0
1
2
3
1.9 m
3.3 m
13.1 m
ND
Primary
tumor
control
No Yes
ECM Yes No
DS-GPA RPA factors (KPS,
age, extra-cranial
disease status,
control of primary
disease site) and
number of brain
mets
Factor 0 1 2 0.0-1.0
1.5-2.5
3.0
3.5-4.0
3.4m
6.4m
11.6m
14.8m
0.0-1.0
1.5-2.5
3.0
3.5-4.0
3.4m
4.7m
8.8m
13.2m
In melanoma, only
2 significant
prognostic factors:
KPS (p<0.0001)
and number of
brain mets
(p<0.0001)
Sperduto et al.,
2010 [127]KPS <70 70-80 90-100
# of brain
mets
>3 2-3 1
CNS: Central Nervous System; CR: Complete response; DS-GPA: Diagnosis-Specific Graded Prognostic Assessment; ECM:
Extracranial metastases; KPS: Karnofsky performance status; LM: Leptomeningeal metastasis; MM-GKR: Malignant
Melanoma-Gamma Knife Radiosurgery score; ND: Not defined; NED: No evidence of disease; NR: Not reported; OS: Overall
survival; PD: Progressive disease; PI: Prognostic Index; PR: Partial Response; QOL: Quality of life; RPA: Recursive Partitioning
Analysis; SD: Stable disease; SIR: Score Index for Radiosurgery
Table 7. Risk Stratification of Patients with Brain Metastases from Melanoma
An important caveat in discussing outcomes estimates derived using these risk stratification
systems is that they all were first developed prior to 2011. Prior to that time, reliably effective
and proven treatments for advanced melanoma were not available for general clinical use.
Development of drugs with proven activity, such as ipilimumab and vemurafenib discussed
above, are changing the outlook for melanoma patients. This includes patients with brain
metastases. With these drugs, and more being developed with potentially even greater activity,
the risk estimates of these systems will certainly change for the better. This is especially likely
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to be the case in patients with very high risk/poor prognosis disease. Treatment recommen‐
dations for the brain metastasis problem in melanoma will therefore likely be very fluid over
the next several years, as new treatment paradigms for melanoma evolve.
4. Therapy of CNS disease
4.1. Unfavorable/poor risk
By definition, RPA class III patients have a KPS less than 70%. Often, they have multi-focal
brain metastases, active extracranial disease, or both. Historically, their life expectancy was
very limited. The PI prognostic system, intended to assess prognosis in this group as described
above, uses days rather than months as the unit of time for its estimates [43].
Conventionally, surgery or SRS would only be used judiciously with palliative intent and well-
defined goals. WBRT may be undertaken for symptom palliation and a very modest survival
benefit [8, 12, 86, 130-132]. The anticipated duration of survival played an important part in
designing any treatment approach, as even therapy of several weeks duration could consume
a significant proportion of a patient’s remaining lifespan. The burden of coming to repeated
treatments (as might be the case with palliative WBRT, frequently administered as 10 treat‐
ments over 2 weeks) may lead to a significant QOL decrement in patients with poor perform‐
ance status. By definition, RPA class III patients have such a poor performance status.
Prior to the approval in the United States of ipilimumab and vemurafenib in 2011, systemic
therapy played a minimal role in this group. Exceptions included steroid therapy for tumor-
associated edema and anti-convulsants for seizures. The low performance status and CNS
disease in these patients excluded them from virtually all clinical trials. Activity of systemic
agents with CNS penetration, such as temozolmide and fotemustine, was limited, with an
onset of action too slow to benefit most patients with melanoma who were in this category.
As of 2011, BRAF mutational status serves as an important factor in making treatment
decisions. This may be especially important in patients with RPA class III melanoma with CNS
involvement. The BRAF inhibitors vemurafenib and dabrafenib, discussed above, have rapid
onset of action, high response rates, preliminary evidence of CNS activity, oral administration
and manageable toxicity profiles. As of November 2012, vemurafenib is approved in the United
States and Europe, and debrafanib’s approval is pending. For patients possessing an appro‐
priate BRAF mutation, treatment with one of these agents would be reasonable to consider,
even with RPA class III. Of course, the patient must be aware that information about this drug
in the brain metastasis population is presently very limited. Data regarding combinations with
radiotherapy is also very limited at this time. While a clinical trial would be the preferred
setting to treat these patients, use of BRAF inhibition therapy would be reasonable to offer to
BRAF-mutant melanoma patients with brain metastases and RPA class III.
For patients in whom a targetable BRAF mutation is not present, fewer options are available.
Ipilimumab, discussed above, has a relatively slow onset of action, taking 3-4 months in phase
3 trials to confer a survival benefit versus controls [90, 91], with an overall low response rate.
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For someone with a poor performance status unlikely to live that long, ipilimumab is unlikely
to provide benefit, despite preliminary evidence of CNS activity. For these patients, further
developments in melanoma therapy are awaited. Pallitative WBRT likely remains the standard
therapy for these patients.
One peculiar circumstance remains: some patients present with RPA class III advanced disease,
including brain metastases and poor performance status, but their BRAF mutational status is
unknown. Given their overall condition and location of disease, obtaining a tumor specimen
to determine BRAF mutation status may not be possible. A wait of 1-2 weeks for results of
mutational testing may consume a significant portion of their remaining lifespan. In such
patients, standard care would be supportive, potentially with the addition of WBRT. Given a
frequency of BRAF mutations targeted by presently available drugs of about 50% and the lack
of other proven options, a therapeutic trial of BRAF inhibition is unlikely to cause significant
harm, and might lead to dramatic benefit if the patient possesses an appropriate mutation.
Again, before embarking on such a treatment course, the patient must be aware of the
limitations of our current dataset.
4.2. Favorable/good risk
Patients of RPA class I have a relatively good prognosis and warrant an aggressive treatment
approach. Such patients are young, have a good performance status, and no active extracranial
disease. However, among patients with metastatic melanoma, true RPA class I patients are
infrequently encountered, especially those completely lacking detectable extracranial disease.
The major treatment decision for these patients relates to local therapy of existing brain lesions
(Figure 1). The goal would be to treat all evident CNS disease by some form of definitive
therapy (surgery or SRS). Traditionally, surgery was favored in cases involving one surgically
accessible lesion, and benefit was reported in surgeries targeting up to 3 lesions [14, 133].
Surgery is also especially useful in specific situations where SRS is less favorable, such as large
lesion size (> 3cm) or symptomatology (for example, bleeding). Surgery also yields a specimen
to confirm the diagnosis and analyze for targetable alterations in the tumor, such as BRAF
mutations status. In patients lacking any other evident disease, these data can be very impor‐
tant and only obtainable from a surgically resected CNS specimen. Otherwise, SRS is emerging
as the preferred local therapy, both for its simpler administration and possibly for better local
control [44]. SRS may also be able to provide definitive treatment at sites inaccessible to
surgery. Surgery and SRS are not mutually exclusive: both may be necessary to provide
definitive treatment of all lesions in multi-focal metastatic CNS disease.
SRS has been a remarkable addition to our armamentarium for treatment of brain metastases.
Previously, surgery was the only approach to definitive treatment. If more than 3 lesions were
present, or they were located in surgically inaccessible locations, surgery could not be used
with the intention of long-term control. SRS allows treatment of multiple lesions, in sites
inaccessible to surgery. It also offers the possibility of re-treatment. At some point, presumably,
the number of lesions exceeds the ability of SRS to control the disease. The exact number is not
defined, but some have advocated SRS to control up to five CNS lesions [37]. Beyond this, it
may be unreasonable to expect a local treatment modality like SRS to control what is clinically
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widespread involvement in an organ system, even if limited to the CNS. Surgery and SRS may
be able to control specific lesions that are symptomatic in such patients, but the overall
treatment approach relies primarily on therapeutic WBRT and systemic therapy, discussed
below under “Intermediate Risk.”
In patients with RPA class I disease from melanoma, risk of failure in the CNS is high if
treatment focuses solely on radiologically evident disease. This likely reflects the underlying
biology, in which specific neurotropic sub-clones of melanoma develop that colonize the CNS,
leading to brain metastases. Limiting treatment to surgery and/or SRS of only radiologically
evident lesions ignores this biological reality. This observation is confirmed in the multiple
randomized trials of adjuvant WBRT enrolling patients with multiple tumor types, including
melanoma. Adjuvant WBRT decreases intracranial recurrence rates when combined with
definitive local therapy. This effect is evident at both definitively treated macroscopic sites
(treating residual contamination) and at distant sites within the CNS. At distant sites, adjuvant
WBRT must accomplish this by either treating pre-existing radiologically undetectable
micrometastatic disease or making the CNS less receptive to colonization from extracranial
sites. The former is the more plausible biological explanation.
Approaches to address the problem of distant CNS recurrence have been discussed in detail
earlier. Basically, these come down to either administering adjuvant WBRT up-front, or using
an expectant management strategy, with regular imaging and re-treatment (primarily with
SRS), at the time of CNS progression. Arguments against adjuvant WBRT include concern
regarding its cognitive toxicity, its lack of clear survival benefit and inability to undertake re-
treatment. As described earlier, cognitive effects of adjuvant WBRT, while not absent, are not
unreasonable in the setting of CNS metastases, especially when balanced against the cognitive
effects of tumor progression and those of re-treatment (as, for example, by SRS). Adjuvant
WBRT is unlikely to be associated, in general, with an overall survival benefit overall due to
extracranial disease as a competing cause of death. In the setting of RPA class I patients, who
lack active extracranial disease, adjuvant WBRT may very well have a survival benefit [54, 134].
As noted above, the use of a salvage strategy, relying on SRS in the event of tumor progression,
is associated with high rates of intracranial failure. The cognitive effects of such a strategy have
not been assessed in detail, but the data regarding cognitive effects of allowing tumor pro‐
gression have been reviewed and are clearly unfavorable. Whether the effects are better or
worse than those due to adjuvant use of WBRT can only be answered by a randomized
comparison of the two strategies.
We concede that the decision regarding use of adjuvant WBRT is not simple and clear-cut. To
determine whether to recommend its use, the benefit of decreased intracranial progression
rates must be balanced against its adverse effects. Overall, we believe that the published
evidence generally supports the use of adjuvant WBRT in melanoma patients.
Systemic adjuvant therapy might be an alternative to adjuvant WBRT. Traditional cytotoxic
therapy agents with known CNS activity, such as fotemustine or temozolomide, have not been
shown clearly to impact the subsequent development of CNS disease in melanoma patients
[113, 135]. In the setting of melanoma patients with CNS disease, their primary purpose was
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to treat extracranial disease, an important prognostic factor once CNS disease was controlled.
By definition, true RPA class I patients have no active extracranial disease.
Newly developed agents, such as vemurafenib and ipilimumab, may have a role defined in
the future for adjuvant therapy in patients with RPA class I CNS disease from melanoma. They
may be able to affect both CNS recurrence rates and progression of extracranial disease.
However, data supporting such use is not available at present. Their use as adjuvant therapies
in this population is not warranted, outside the setting of a clinical trial.
Figure 1. Treatment of melanoma patients with brain metastases with favorable risk profile, equivalent to RPA class I.
In patients with more than one brain lesion who are to receive local therapy, it may be necessary to use both surgery
and radiosurgery to treat all lesions. By definition, RPA class I patients have no active extracranial disease. Thus, sys‐
temic therapy is not indicated except in an experimental trial. CNS: central nervous system; KPS: Karnofsky perform‐
ance status; RPA: Recursive Partitioning Analysis; SRS: stereotactic radiosurgery; WBRT: whole brain radiotherapy.
4.3. Intermediate risk
Treatment decisions in intermediate risk patients (equivalent to RPA class II) are probably
most difficult of all (Figure 2). This relates to their variable clinical presentation. They have
better performance status than those with unfavorable RPA class III. They are also of advanced
age (according to RPA, anyone older than 65 years), have active extracranial disease, or both,
conveying a negative prognosis relative to RPA class I. A logical way to divide this population
is into those with CNS disease amenable to local definitive therapy and those with CNS disease
too extensive for complete, definitive local therapy of all lesions.
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Considerations regarding the use of adjuvant WBRT and the desirability for treatment in the
context of a clinical trial are essentially the same as for favorable prognosis patients. The key
differentiating question is whether local therapy of CNS lesions with surgery or SRS should
be attempted at all. Several clinical situations argue against their use. Lesions may be inacces‐
sible for surgery or too large for SRS or they may simply be too numerous. If definitive
treatment of all CNS disease sites is possible, then it should be attempted. If CNS disease is
not amenable to local therapy of all lesions, then treatment must rely on therapeutic WBRT
and systemic therapy, with surgery or SRS reserved for large or symptomatic lesions.
Figure 2. Treatment of melanoma patients with brain metastases with intermediate prognosis, equivalent to RPA class II. In
patients with more than one brain lesion who are to receive local therapy, it may be necessary to use both surgery and radio‐
surgery to treat all lesions. Patients with active extracranial disease should be considered for systemic therapy. While in the
past, few active systemic agents were available, newer therapies might have relevance early in the treatment of intermedi‐
ate prognosis patients. For example, BRAF inhibition with vemurafenib has rapid onset of control, high response rates, and
even preliminary evidence of CNS activity. Thus, early use of systemic therapy might be able to impact both CNS disease and
extracranial disease. Extracranial disease activity is a consistent adverse prognostic factor in intermediate patients, once
CNS disease is controlled. CNS: central nervous system; KPS: Karnofsky performance status; RPA: Recursive Partitioning
Analysis; SRS: stereotactic radiosurgery; WBRT: whole brain radiotherapy.
In RPA class II patients with CNS melanoma, active extracranial disease status is a key prog‐
nostic factor. Disease outside the CNS represents a competing cause of death. Before the ap‐
proval in 2011-2012 of agents with proven anti-melanoma activity (such as vemurafenib and
ipilimumab), systemic therapy of the CNS was limited to temozolomide or fotemustine (in
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Europe). Although these drugs treated extracranial disease as well, they were not highly ac‐
tive in either the CNS or extracranial compartments, and did not demonstrate clear or dra‐
matic survival benefits.
Systemic therapy of melanoma in RPA class II patients is appearing brighter than it has in the
past. Clinical trials are opening which permit these patients to enroll, and highly active agents,
with CNS activity moreover, such as vemurafenib are available non-experimentally for
patients with BRAF mutations. For patients lacking BRAF mutations, treatment with ipilimu‐
mab is a reasonable consideration, due to its survival benefit in a phase 3 trial, which included
patients with pre-existing, treated brain metastases [90]. Most of these patients will live long
enough to derive benefit from ipilimumab. As new agents are developed, their use in RPA
class II melanoma patients is justified, even without demonstrable CNS activity, due to the
active extracranial disease present in most of this population as a competing cause of death.
5. Directions for the future
Brain metastasis is part of the natural history of metastatic melanoma. It is a common problem
and has a major adverse impact on treatment outcomes and QOL. The bulk of melanoma-
specific research consists of retrospective analyses and single-center studies. Prospectively
validated, comprehensive treatment paradigms do not yet exist. The preceding discussion
suggests some important research questions for the future.
Optimal use of SRS technology remains undefined. One question relates to the treatment of
multiple lesions. The only major randomized trial of SRS in brain metastasis therapy demonstrat‐
ed a survival benefit in the presence of only a single brain metastasis [15]. No prospective data
support a survival benefit from SRS when more than one lesion is present; retrospective data from
several sources indicate that multiple CNS lesions are associated with worse survival [22, 26, 35].
At some point, the absolute number of CNS lesions poses a barrier to effective SRS therapy.
Some argue that the presence of multiple lesions (up to about 5) should not preclude therapy,
based on results indicating that the number of CNS melanoma lesions did not predict subse‐
quent survival [39, 136]. Whether some threshold number of lesions exists is an unanswered
question appropriate for investigation.
SRS itself is a generic term for a rapidly evolving technology. The relevance of even recently
published results to current treatment technologies may be questioned. What is unlikely to
change is the local nature of SRS therapy: SRS treats the radiated region, but not that which is
unradiated. As discussed extensively, concurrent micrometastatic disease is not addressed by
SRS, as it is also not by surgery. The use of adjuvant therapy after local treatment with surgery
or SRS lacks melanoma-specific prospective data. Five randomized trials, described above,
indicate that adjuvant WBRT can decrease intracranial recurrence rates, both at sites treated
with surgery/SRS and at untreated sites. The adverse neurocognitive effects of WBRT and the
efficacy of this modality in the metastatic melanoma population are valid questions. As noted
above, such a study is in progress (NCT01503827) [55].
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An alternative to the use of adjuvant WBRT is a planned radiosurgical salvage strategy. This
presumably minimizes exposure of the CNS to WBRT and its adverse effects. Little data is
available regarding this treatment approach. A randomized clinical trial would be most
helpful, in which patients are randomized to receive immediate adjuvant WBRT after SRS
therapy or undergo planned SRS salvage treatments, with WBRT only when SRS is not
possible. This study would provide data to balance the neurocognitive consequences of
immediate WBRT with those due to an increased rate of later macroscopic CNS progression.
Further, some estimate of the neurocognitive cost of SRS re-treatment would be obtained.
SRS itself is used for adjuvant purposes after surgical metastectomy to treat residual disease
at the resection site. The efficacy of this has not been defined. Additionally, such therapy does
not treat occult disease at other sites within the CNS. A randomized trial comparing the efficacy
of adjuvant SRS to either no adjuvant therapy or to adjuvant WBRT would be appropriate.
Finally, and perhaps most significantly, systemic therapy of melanoma is evolving rapidly, and
those advances will have a major impact on treatment of CNS disease. Even now, convincing
preliminary evidence of CNS activity of these several new agents has been presented. Previous‐
ly, melanoma patients with CNS disease were excluded from clinical trials in the belief that the
blood-brain barrier posed to great a hurdle to clinical efficacy. This no longer appears to be a valid
assumption. As new agents emerge, their activity in the CNS should either be addressed in CNS-
specific trials, or patients with CNS melanoma should be considered similar to any other
melanoma patient, so long as their CNS disease is minimally or asymptomatic.
Much of this review has focused on the controversy of adjuvant therapy in the CNS. Adjuvant
WBRT is not an optimal solution to this problem. It does not prevent CNS re-seeding from
extracranial sites and cannot be used repeatedly. Adverse cognitive effects of WBRT are clearly
demonstrable, even if their clinical impact is arguable. Critically, adjuvant WBRT also does
not address the problem of extracranial disease, a major prognostic factor. Optimal adjuvant
therapy to address these limitations is likely to be systemic. The development of highly active
agents with CNS penetration opens the possibility of their use in melanoma patients after
definitive treatment of brain metastases.
Several prior studies can provide necessary baseline data regarding rates of CNS progression
for sample size calculations [113, 135]. Neurocognitive effects must be a secondary endpoint
in any study, as it cannot be assumed that systemic agents are devoid of adverse neurocognitive
effects. For example, case reports of melanoma patients treated with fotemustine reported toxic
leukoencephalopathy with progressive dementia in several patients, [137, 138].
6. Conclusions
Brain metastasis is a frequent and serious problem for melanoma patients. New technologies,
such as SRS and agents, such as vemurafenib and ipilimumab, are expanding our ability to
treat this condition. Melanoma-specific studies guiding optimal employment of new technol‐
ogies are limited. Most information regarding CNS treatment in melanoma is extrapolated
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from other conditions or is based on retrospective analyses from individual centers. Data from
well-designed, prospective trials is lacking in many regards. This deficiency has been noted at
least eight years previously by others [139]. At present, many of the same questions posed by
those workers remain unanswered. Fortunately, melanoma treatment itself has not remained
static, with new agents generating new questions regarding optimal treatment of the condition.
Well-designed, rigorous trials will allow our patients to receive the best and most cost-effective
treatments available. Melanoma patients with brain metastases can look forward to a brighter
future. We must, however, demand rigorous investigations to allow the best use possible of
the arsenal being placed at our disposal to treat this challenging problem.
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